Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• "Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research?1 passage
• "L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial".1 passage
• "Normal" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis.1 passage
• 'Letter to the editor: Response to letter concerning our patient with post-vaccination autoimmune hepatitis like syndrome'.1 passage
• 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.1 passage
• 17-Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury.1 passage
• 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.1 passage
• 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD81 passage
• 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.1 passage
• 5-Hydroxytryptamine Receptor 1D Aggravates Hepatocellular Carcinoma Progression Through FoxO6 in AKT-Dependent and Independent Manners.1 passage
• A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.1 passage
• A Bioreactor Technology for Modeling Fibrosis in Human and Rodent Precision-Cut Liver Slices.1 passage
• A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease.1 passage
• A Case of Sphenoid Sinus Metastasis in Hepatocellular Carcinoma.1 passage
• A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers.1 passage
• A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.1 passage
• A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.1 passage
• A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.1 passage
• A Functional Variant in Ubiquitin Conjugating Enzyme E2 L3 Contributes to Hepatitis B Virus Infection and Maintains Covalently Closed Circular DNA Stability by Inducing Degradation of Apolipoprotein B mRNA Editing Enzyme Catalytic Subunit 3A.1 passage
• A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome.1 passage
• A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis.1 passage
• A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.1 passage
• A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.1 passage
• A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.1 passage
• A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.1 passage
• A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.1 passage
• A Metallomic Approach to Assess Associations of Serum Metal Levels With Gallstones and Gallbladder Cancer.1 passage
• A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.1 passage
• A Model for Glomerular Filtration Rate Assessment in Liver Disease (GRAIL) in the Presence of Renal Dysfunction.1 passage
• A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India.1 passage
• A Model to Predict 1-Month Risk of Transplant or Death in Hepatitis A-Related Acute Liver Failure.1 passage
• A Model to predict severity of drug-induced liver injury in humans.1 passage
• A Molecular Mechanism Underlying Genotype-Specific Intrahepatic Cholestasis Resulting From MYO5B Mutations.1 passage
• A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.1 passage
• A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma.1 passage
• A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation.1 passage
• A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.1 passage
• A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression.1 passage
• A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study.1 passage
• A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding.1 passage
• A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.1 passage
• A Prospective Study Identifying Predictive Factors of Cardiac Decompensation After Transjugular Intrahepatic Portosystemic Shunt: The Toulouse Algorithm.1 passage
• A Randomized Clinical Trial of Fecal Microbiota Transplant for Alcohol Use Disorder.1 passage
• A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection.1 passage
• A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma.1 passage
• A Roadmap for Value-Based Payment Models Among Patients With Cirrhosis.1 passage
• A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.1 passage
• A Transforming Growth Factor-β and H19 Signaling Axis in Tumor-Initiating Hepatocytes That Regulates Hepatic Carcinogenesis.1 passage
• A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection.1 passage
• A clinicopathological cohort study of liver pathology in 301 patients with human immunodeficiency virus/acquired immune deficiency syndrome.1 passage
• A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma.1 passage
• A fixed partial epithelial-mesenchymal transition (EMT) triggers carcinogenesis, whereas asymmetrical division of hybrid EMT cells drives cancer progression.1 passage
• A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance.1 passage
• A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation.1 passage
• A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3.1 passage
• A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.1 passage
• A hMTR4-PDIA3P1-miR-125/124-TRAF6 Regulatory Axis and Its Function in NF kappa B Signaling and Chemoresistance.1 passage
• A highly specific and sensitive hepatitis C virus antigen enzyme immunoassay for One-step diagnosis of viremic hepatitis C virus infection.1 passage
• A liver-specific gene expression panel predicts the differentiation status of in vitro hepatocyte models.1 passage
• A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis.1 passage
• A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.1 passage
• A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy.1 passage
• A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.1 passage
• A nationwide survey of hepatitis E viral infection in French blood donors.1 passage
• A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.1 passage
• A new HIF-1α/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice.1 passage
• A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.1 passage
• A new horizon in the prevention of the postembolization syndrome after transcatheter arterial chemoembolization for hepatocellular carcinoma.1 passage
• A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation.1 passage
• A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice.1 passage
• A novel long noncoding RNA Lnc-HC binds hnRNPA2B1 to regulate expressions of Cyp7a1 and Abca1 in hepatocytic cholesterol metabolism.1 passage
• A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers.1 passage
• A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians.1 passage
• A novel role for CRTC2 in hepatic cholesterol synthesis through SREBP-2.1 passage
• A novel role of astrocyte elevated gene-1 (AEG-1) in regulating nonalcoholic steatohepatitis (NASH).1 passage
• A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner.1 passage
• A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.1 passage
• A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation.1 passage
• A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR-OLT score.1 passage
• A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha.1 passage
• A practical approach to nutritional screening and assessment in cirrhosis.1 passage
• A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis.1 passage
• A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization.1 passage
• A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.1 passage
• A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis.1 passage
• A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.1 passage
• A risk score to predict the development of hepatic encephalopathy in a population-based cohort of patients with cirrhosis.1 passage
• A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses.1 passage
• ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis.1 passage
• ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.1 passage
• APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort.1 passage
• Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study.1 passage
• Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.1 passage
• Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis.1 passage
• Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1,827 Patients in a Major U.S. Hospital Network.1 passage
• Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach.1 passage
• Acetyl-coenzyme A carboxylase alpha promotion of glucose-mediated fatty acid synthesis enhances survival of hepatocellular carcinoma in mice and patients.1 passage
• Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.1 passage
• Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis.1 passage
• Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis in mice.1 passage
• Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition.1 passage
• Activated Protein Phosphatase 2A Disrupts Nutrient Sensing Balance Between Mechanistic Target of Rapamycin Complex 1 and Adenosine Monophosphate-Activated Protein Kinase, Causing Sarcopenia in Alcohol-Associated Liver Disease.1 passage
• Activating Adenosine Monophosphate-Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice.1 passage
• Activation of Estrogen Receptor G Protein-Coupled Receptor 30 Enhances Cholesterol Cholelithogenesis in Female Mice.1 passage
• Activation of Pregnane X Receptor Sensitizes Mice to Hemorrhagic Shock-Induced Liver Injury.1 passage
• Activation of aryl hydrocarbon receptor dissociates fatty liver from insulin resistance by inducing fibroblast growth factor 21.1 passage
• Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B(-/-) (Wilson disease) mice.1 passage
• Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation.1 passage
• Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes.1 passage
• Activation of the c-Jun N-terminal kinase pathway aggravates proteotoxicity of hepatic mutant Z alpha1-antitrypsin.1 passage
• Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.1 passage
• Acute Hepatitis Is a Prominent Presentation of the Multisystem Inflammatory Syndrome in Children: A Single-Center Report.1 passage
• Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypo-coagulable and Hyper-coagulable Features.1 passage
• Acute Liver Failure (ALF) in Pregnancy: How Much Is Pregnancy Related?1 passage
• Acute Liver Injury With Therapeutic Doses of Acetaminophen: A Prospective Study.1 passage
• Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large U.S. Cohort.1 passage
• Acute and Chronic Hepatitis E Virus Infection in Human Immunodeficiency Virus-Infected U.S. Women.1 passage
• Acute hepatic porphyrias: Recommendations for evaluation and long-term management.1 passage
• Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.1 passage
• Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties.1 passage
• Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality.1 passage
• Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?1 passage
• Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults.1 passage
• Acyl-Coenzyme A Thioesterase 9 Traffics Mitochondrial Short-Chain Fatty Acids Toward De Novo Lipogenesis and Glucose Production in the Liver.1 passage
• Ad Libitum Mediterranean and Low-Fat Diets Both Significantly Reduce Hepatic Steatosis: A Randomized Controlled Trial.1 passage
• Adaptation of the hepatitis B virus core protein to CD8(+) T-cell selection pressure.1 passage
• Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients.1 passage
• Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study).1 passage
• Addressing Social Adversity to Improve Outcomes for Children After Liver Transplant.1 passage
• Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action.1 passage
• Adjuvant Treatment of Hepatocellular Carcinoma: Prospect of Immunotherapy.1 passage
• Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement.1 passage
• Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis.1 passage
• Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.1 passage
• Advance care planning (ACP) for specialists managing cirrhosis: A focus on patient-centered care.1 passage
• Advanced Techniques and Awaited Clinical Applications for Human Pluripotent Stem Cell Differentiation into Hepatocytes.1 passage
• Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B.1 passage
• Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice.1 passage
• Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease.1 passage
• Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic sirtuin 1-C/EBPα-miRNA-223 axis.1 passage
• Aging-Related Expression of Twinfilin-1 Regulates Cholangiocyte Biological Response to Injury.1 passage
• Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis.1 passage
• Albumin in Advanced Liver Diseases: The Good and Bad of a Drug!1 passage
• Alcohol abstinence ameliorates the dysregulated immune profiles in patients with alcoholic hepatitis: A prospective observational study.1 passage
• Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival.1 passage
• Alcohol-Related Liver Disease: Areas of Consensus, Unmet Needs and Opportunities for Further Study.1 passage
• Alcoholic hepatitis: Translational approaches to develop targeted therapies.1 passage
• Aldehyde dehydrogenase-2 (ALDH2) opposes hepatocellular carcinoma progression by regulating AMP-activated protein kinase signaling in mice.1 passage
• Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.1 passage
• All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.1 passage
• All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.1 passage
• Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial.1 passage
• Alpha-1 Antitrypsin Deficiency Liver Disease, Mutational Homogeneity Modulated by Epigenetic Heterogeneity With Links to Obesity.1 passage
• Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.1 passage
• Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.1 passage
• Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.1 passage
• Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.1 passage
• Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA.1 passage
• American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.1 passage
• Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.1 passage
• An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017.1 passage
• An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People.1 passage
• An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study.1 passage
• An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD.1 passage
• An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis.1 passage
• An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States.1 passage
• An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis.1 passage
• An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection.1 passage
• An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial.1 passage
• An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice.1 passage
• An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of kupffer cell polarization.1 passage
• Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model.1 passage
• Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase.1 passage
• Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Micro-scalable Hepatic Co-culture System.1 passage
• Analysis of Survival Benefits of Living Versus Deceased Donor Liver Transplant in High Model for End-Stage Liver Disease and Hepatorenal Syndrome.1 passage
• Analysis of aberrant pre-messenger RNA splicing resulting from mutations in ATP8B1 and efficient in vitro rescue by adapted U1 small nuclear RNA.1 passage
• Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis.1 passage
• Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region.1 passage
• Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease.1 passage
• Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.1 passage
• Annexin A6 Is Critical to Maintain Glucose Homeostasis and Survival During Liver Regeneration in Mice.1 passage
• Antegrade embolization of spontaneous splenorenal shunt for post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy.1 passage
• Anti-TNF-α for necrotizing sarcoid granulomatosis of the liver.1 passage
• Antibiotic prophylaxis in cirrhosis: Good and bad.1 passage
• Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.1 passage
• Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity.1 passage
• Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.1 passage
• Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis.1 passage
• Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis.1 passage
• Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis.1 passage
• Antiviral treatment and liver-related complications in hepatitis delta.1 passage
• Apolipoprotein E and protection against hepatitis E viral infection in American non-Hispanic blacks.1 passage
• Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles.1 passage
• Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.1 passage
• Application of Artificial Intelligence for the Diagnosis and Treatment of Liver Diseases.1 passage
• Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review.1 passage
• Appraisal of Cardiac Ejection Fraction With Liver Disease Severity: Implication in Post-Liver Transplantation Mortality.1 passage
• Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis.1 passage
• Aquaporin 9 Induction in Human iPSC-derived Hepatocytes Facilitates Modeling of Ornithine Transcarbamylase Deficiency.1 passage
• Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of Recommendations.1 passage
• Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.1 passage
• Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk.1 passage
• Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas.1 passage
• Aspartate aminotransferase to platelet ratio and fibrosis-4 as biomarkers in biopsy-validated pediatric cystic fibrosis liver disease.1 passage
• Aspartate β-hydroxylase modulates cellular senescence through glycogen synthase kinase 3β in hepatocellular carcinoma.1 passage
• Aspirin use and the risk of cholangiocarcinoma.1 passage
• Assessing the Time-Dependent Impact of Performance Status on Outcomes After Liver Transplantation.1 passage
• Assessing the therapeutic potential of lab-made hepatocytes.1 passage
• Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy.1 passage
• Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: An individual patient data-based meta-analysis.1 passage
• Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis.1 passage
• Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.1 passage
• Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation.1 passage
• Association of Metabolic Risk Factors With Risks of Cancer and All-Cause Mortality in Patients With Chronic Hepatitis B.1 passage
• Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.1 passage
• Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.1 passage
• Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study.1 passage
• Association of vitamin E intake at early childhood with alanine aminotransferase levels at mid-childhood.1 passage
• Associations Between Intake of Sugar-Containing Beverages in Infancy With Liver Fat Accumulation at School Age.1 passage
• Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women.1 passage
• Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: Results from ERCHIVES.1 passage
• Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up.1 passage
• Autoimmune hepatitis in a murine autoimmune polyendocrine syndrome type 1 model is directed against multiple autoantigens.1 passage
• Autophagy determines efficiency of liver-directed gene therapy with adeno-associated viral vectors.1 passage
• Autoreactive monoclonal antibodies from patients with primary biliary cholangitis recognize environmental xenobiotics.1 passage
• Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma.1 passage
• B lymphocytes limit senescence-driven fibrosis resolution and favor hepatocarcinogenesis in mouse liver injury.1 passage
• BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.1 passage
• Baicalein Targets GTPase-Mediated Autophagy to Eliminate Liver Tumor-Initiating Stem Cell-Like Cells Resistant to mTORC1 Inhibition.1 passage
• Bariatric surgery for nonalcoholic steatohepatitis: A clinical and cost-effectiveness analysis.1 passage
• Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.1 passage
• Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.1 passage
• Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level.1 passage
• Basolateral CD147 induces hepatocyte polarity loss by E-cadherin ubiquitination and degradation in hepatocellular carcinoma progress.1 passage
• Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.1 passage
• Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial.1 passage
• Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.1 passage
• Bespoken Nanoceria: An Effective Treatment in Experimental Hepatocellular Carcinoma.1 passage
• Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.1 passage
• Biallelic Mutations in Tetratricopeptide Repeat Domain 26 (Intraflagellar Transport 56) Cause Severe Biliary Ciliopathy in Humans.1 passage
• Biases in the reporting of hepatocellular carcinoma tumor sizes on the liver transplant waiting list.1 passage
• Bidirectional Role of NLRP3 During Acute and Chronic Cholestatic Liver Injury.1 passage
• Bidirectional transendothelial migration of monocytes across hepatic sinusoidal endothelium shapes monocyte differentiation and regulates the balance between immunity and tolerance in liver.1 passage
• Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation.1 passage
• Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.1 passage
• Bile acids stimulate cholangiocyte fluid secretion by activation of transmembrane member 16A Cl1 passage
• Bile salt export pump-reactive antibodies form a polyclonal, multi-inhibitory response in antibody-induced bile salt export pump deficiency.1 passage
• Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile.1 passage
• Biliary Atresia: Clinical and Research Challenges for the Twenty-First Century.1 passage
• Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.1 passage
• Biological Nanotherapeutics for Liver Disease.1 passage
• Biology and Clinical Application of Regulatory RNAs in Hepatocellular Carcinoma.1 passage
• Biomarkers for Hepatobiliary Cancers.1 passage
• Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis.1 passage
• Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States.1 passage
• Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.1 passage
• Bleeding complications in acute liver failure.1 passage
• Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr21 passage
• Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.1 passage
• Bone Density in Children With Chronic Liver Disease Correlates With Growth and Cholestasis.1 passage
• Bone Morphogenetic Protein 9 Is a Paracrine Factor Controlling Liver Sinusoidal Endothelial Cell Fenestration and Protecting Against Hepatic Fibrosis.1 passage
• Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1-antitrypsin.1 passage
• Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver.1 passage
• Brahma-Related Gene 1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.1 passage
• Breviscapine Alleviates Nonalcoholic Steatohepatitis by Inhibiting TGF-β-activated Kinase 1-dependent Signaling.1 passage
• Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.1 passage
• Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States.1 passage
• C/EBP homologous protein-induced loss of intestinal epithelial stemness contributes to bile duct ligation-induced cholestatic liver injury in mice.1 passage
• C/EBPα-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer.1 passage
• C24-Ceramide Drives Gallbladder Cancer Progression Through Directly Targeting Phosphatidylinositol 5-Phosphate 4-Kinase Type-2 Gamma to Facilitate Mammalian Target of Rapamycin Signaling Activation.1 passage
• CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.1 passage
• CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma.1 passage
• CCBE1 mutation causing sclerosing cholangitis: Expanding the spectrum of lymphedema-cholestasis syndrome.1 passage
• CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma.1 passage
• CD141 passage
• CD14 is associated with biliary stricture formation.1 passage
• CD2-Associated Protein Contributes to Hepatitis C, Virus Propagation and Steatosis by Disrupting Insulin Signaling.1 passage
• CD41 passage
• CD47-Mediated Hedgehog/SMO/GLI1 Signaling Promotes Mesenchymal Stem Cell Immunomodulation in Mouse Liver Inflammation.1 passage
• CD97 Promotes Tumor Aggressiveness Through the Traditional G Protein-Coupled Receptor-Mediated Signaling in Hepatocellular Carcinoma.1 passage
• CIDEC/FSP27 is regulated by peroxisome proliferator-activated receptor alpha and plays a critical role in fasting- and diet-induced hepatosteatosis.1 passage
• CRAF Methylation by PRMT6 Regulates Aerobic Glycolysis-Driven Hepatocarcinogenesis via ERK-Dependent PKM2 Nuclear Relocalization and Activation.1 passage
• CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.1 passage
• CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis.1 passage
• Calcium-binding protein 39 promotes hepatocellular carcinoma growth and metastasis by activating extracellular signal-regulated kinase signaling pathway.1 passage
• Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.1 passage
• Cancer Stem cells and their cellular origins in primary liver and biliary tract cancers.1 passage
• Cancer-Associated Fibroblast-Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression.1 passage
• Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort.1 passage
• Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.1 passage
• Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin-1/Mechanistic Target of Rapamycin Complex 2 and 5'Adenosine Monophosphate-Activated Protein Kinase Signaling.1 passage
• Canonical NF-κB signaling in hepatocytes acts as a tumor-suppressor in hepatitis B virus surface antigen-driven hepatocellular carcinoma by controlling the unfolded protein response.1 passage
• Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis.1 passage
• Carboxylesterase 2 prevents liver steatosis by modulating lipolysis, endoplasmic reticulum stress, and lipogenesis and is regulated by hepatocyte nuclear factor 4 alpha in mice.1 passage
• Carcinoembryonic antigen-related cell adhesion molecule 1 controls IL-2-dependent regulatory T-cell induction in immune-mediated hepatitis in mice.1 passage
• Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.1 passage
• Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C.1 passage
• Cardiolipin Synthase 1 Ameliorates NASH Through Activating Transcription Factor 3 Transcriptional Inactivation.1 passage
• Cardiovascular predictors of death in patients with cirrhosis.1 passage
• Care delivery and outcomes among US veterans with hepatitis B: A national cohort study.1 passage
• Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.1 passage
• Caspase Recruitment Domain Protein 6 Protects Against Hepatic Steatosis and Insulin Resistance by Suppressing Apoptosis Signal-Regulating Kinase 1.1 passage
• Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.1 passage
• Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports.1 passage
• Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study.1 passage
• Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.1 passage
• Cd11b(+) myeloid cells support hepatic metastasis through down-regulation of angiopoietin-like 7 in cancer cells.1 passage
• Cell death markers in patients with cirrhosis and acute decompensation.1 passage
• Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer.1 passage
• Cellular Membrane Trafficking Machineries Used by the Hepatitis Viruses.1 passage
• Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.1 passage
• Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma.1 passage
• Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.1 passage
• Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy.1 passage
• Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis.1 passage
• Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.1 passage
• Changing Epidemiology of Hepatitis A in China: Evidence From Three National Serological Surveys and the National Notifiable Disease Reporting System.1 passage
• Changing Trends in Etiology-Based and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United States.1 passage
• Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program.1 passage
• Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma.1 passage
• Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection.1 passage
• Characterization and Application of Precore/Core-Related Antigens in Animal Models of Hepatitis B Virus Infection.1 passage
• Characterization of Acute HCV Infection and Transmission Networks in People Who Currently Inject Drugs in Catalonia: Usefulness of Dried Blood Spots.1 passage
• Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma.1 passage
• Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury.1 passage
• Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.1 passage
• Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus.1 passage
• Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma.1 passage
• Characterizing Hepatitis C Virus-Specific CD41 passage
• Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.1 passage
• Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients.1 passage
• Chemokine (C-X-C motif) ligand 13 promotes intrahepatic chemokine (C-X-C motif) receptor 5+ lymphocyte homing and aberrant B-cell immune responses in primary biliary cirrhosis.1 passage
• Chemokine (C-X-C motif) receptor 3-positive B cells link interleukin-17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma.1 passage
• Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study.1 passage
• Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.1 passage
• Cholangiocyte-Derived Exosomal Long Noncoding RNA H19 Promotes Hepatic Stellate Cell Activation and Cholestatic Liver Fibrosis.1 passage
• Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.1 passage
• Cholemic Nephropathy Causes Acute Kidney Injury and Is Accompanied by Loss of Aquaporin 2 in Collecting Ducts.1 passage
• Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma.1 passage
• Chronic Hepatitis B Prevalence Among Foreign-Born and U.S.-Born Adults in the United States, 1999-2016.1 passage
• Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.1 passage
• Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD.1 passage
• Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.1 passage
• Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in mice.1 passage
• Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces.1 passage
• Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure.1 passage
• Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.1 passage
• Circular RNA MAT2B Promotes Glycolysis and Malignancy of Hepatocellular Carcinoma Through the miR-338-3p/PKM2 Axis Under Hypoxic Stress.1 passage
• Circular RNA Sequencing Identifies CircASAP1 as a Key Regulator in Hepatocellular Carcinoma Metastasis.1 passage
• Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression.1 passage
• Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis.1 passage
• Circulating Kidney Injury Molecule 1 Predicts Prognosis and Poor Outcome in Patients With Acetaminophen-Induced Liver Injury.1 passage
• Circulating let-7 levels in plasma and extracellular vesicles correlate with hepatic fibrosis progression in chronic hepatitis C.1 passage
• Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients.1 passage
• Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma.1 passage
• Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis.1 passage
• Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality.1 passage
• Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander.1 passage
• Cirrhotic Cardiomyopathy in Children With Biliary Atresia: A New Objective Parameter to Predict Morbidity and Mortality on the Wait List-and Beyond!1 passage
• Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.1 passage
• Clinical Consequences of Cardiomyopathy in Children With Biliary Atresia Requiring Liver Transplantation.1 passage
• Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.1 passage
• Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis.1 passage
• Clinical Features of Patients Infected With Coronavirus Disease 2019 With Elevated Liver Biochemistries: A Multicenter, Retrospective Study.1 passage
• Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.1 passage
• Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.1 passage
• Clinical Manifestations and Outcomes of Patients with Sarcomatoid Hepatocellular Carcinoma.1 passage
• Clinical Outcome and Viral Genome Variability of Hepatitis B Virus-Induced Acute Liver Failure.1 passage
• Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation.1 passage
• Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.1 passage
• Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease.1 passage
• Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.1 passage
• Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study.1 passage
• Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.1 passage
• Coagulation Failure in Patients With Acute-on-Chronic Liver Failure and Decompensated Cirrhosis: Beyond the International Normalized Ratio.1 passage
• Coagulation parameters and major bleeding in critically ill patients with cirrhosis.1 passage
• Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure.1 passage
• Colder Weather and Fewer Sunlight Hours Increase Alcohol Consumption and Alcoholic Cirrhosis Worldwide.1 passage
• Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography.1 passage
• Colony-stimulating factor 1 should be considered when studying the miR-28-5p-IL-34-macrophage feedback loop in hepatocellular carcinoma.1 passage
• Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.1 passage
• Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen-Positive Immune Tolerant Chronic Hepatitis B Virus Infection.1 passage
• Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.1 passage
• Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.1 passage
• Combined hepatocellular-cholangiocarcinoma in a patient with Abernethy malformation and tetralogy of Fallot: A case report.1 passage
• Comment on "esophageal balloon tamponade vs. esophageal stent in controlling acute refractory variceal bleeding: A multicenter RCT".1 passage
• Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.1 passage
• Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.1 passage
• Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.1 passage
• Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.1 passage
• Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.1 passage
• Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis.1 passage
• Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis.1 passage
• Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.1 passage
• Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.1 passage
• Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.1 passage
• Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).1 passage
• Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.1 passage
• Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.1 passage
• Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study.1 passage
• Conjugated bilirubin triggers anemia by inducing erythrocyte death.1 passage
• Connective tissue growth factor and integrin αvβ6: a new pair of regulators critical for ductular reaction and biliary fibrosis in mice.1 passage
• Connexin and Pannexin (Hemi)Channels: Emerging Targets in the Treatment of Liver Disease.1 passage
• Consequences of Perioperative Serotonin Reuptake Inhibitor Treatment During Hepatic Surgery.1 passage
• Considerations for Prognosis, Goals of Care, and Specialty Palliative Care for Hospitalized Patients With Acute-on-Chronic Liver Failure.1 passage
• Contextual analysis of determinants of late diagnosis of hepatitis C virus infection in medicare patients.1 passage
• Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure.1 passage
• Contrast-Enhanced Ultrasonography-Based Hepatic Perfusion for Early Prediction of Prognosis in Acute Liver Failure.1 passage
• Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.1 passage
• Coronavirus Disease 2019 Hangover: A Rising Tide of Alcohol Use Disorder and Alcohol-Associated Liver Disease.1 passage
• Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis.1 passage
• Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.1 passage
• Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection.1 passage
• Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis.1 passage
• Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.1 passage
• Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.1 passage
• Cost-effectiveness of strategies for testing current hepatitis C virus infection.1 passage
• Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategies.1 passage
• County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.1 passage
• Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding.1 passage
• Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.1 passage
• Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: An intention-to-treat analysis.1 passage
• Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West.1 passage
• Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19.1 passage
• Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.1 passage
• Cystathionine β-synthase is required for body iron homeostasis.1 passage
• Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients.1 passage
• Cytokine-Producing B Cells Promote Immune-Mediated Bile Duct Injury in Murine Biliary Atresia.1 passage
• Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness.1 passage
• DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.1 passage
• DDX17-regulated alternative splicing that produced a novel oncogenic isoform of PXN-AS1 to promote HCC metastasis.1 passage
• DDX24 Mutations Associated With Malformations of Major Vessels to the Viscera.1 passage
• DEAD Box Protein 5 Inhibits Liver Tumorigenesis by Stimulating Autophagy via Interaction with p62/SQSTM1.1 passage
• DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease.1 passage
• DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection.1 passage
• DNA Methylation Profiling of Human Hepatocarcinogenesis.1 passage
• DNA Methylation of Cannabinoid Receptor Interacting Protein 1 Promotes Pathogenesis of Intrahepatic Cholangiocarcinoma Through Suppressing Parkin-Dependent Pyruvate Kinase M2 Ubiquitination.1 passage
• DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.1 passage
• DNAX Activating Protein of 12 kDa/Triggering Receptor Expressed on Myeloid Cells 2 Expression by Mouse and Human Liver Dendritic Cells: Functional Implications and Regulation of Liver Ischemia-Reperfusion Injury.1 passage
• Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.1 passage
• Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).1 passage
• De Novo Colorectal and Pancreatic Cancer in Liver-Transplant Recipients: Identifying the Higher-Risk Populations.1 passage
• De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.1 passage
• Death and liver transplantation within 2 years of onset of drug-induced liver injury.1 passage
• Deceased Pediatric Donor Livers: How Current Policy Drives Allocation and Transplantation.1 passage
• Decellularized human placenta supports hepatic tissue and allows rescue in acute liver failure.1 passage
• Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ-glutamyltransferase cholestasis.1 passage
• Deficiency in Embryonic Stem Cell Marker Reduced Expression 1 Activates Mitogen-Activated Protein Kinase Kinase 6-Dependent p38 Mitogen-Activated Protein Kinase Signaling to Drive Hepatocarcinogenesis.1 passage
• Deficiency of Mitochondrial Glycerol 3-Phosphate Dehydrogenase Contributes to Hepatic Steatosis.1 passage
• Deficient Natural Killer Cell NKp30-Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma.1 passage
• Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.1 passage
• Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study.1 passage
• Delayed hepatocellular carcinoma model for end-stage liver disease exception score improves disparity in access to liver transplant in the United States.1 passage
• Deletion of Protein Kinase D3 Promotes Liver Fibrosis in Mice.1 passage
• Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice.1 passage
• Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity.1 passage
• Depletion of TRRAP Induces p53-Independent Senescence in Liver Cancer by Down-Regulating Mitotic Genes.1 passage
• Deregulated methionine adenosyltransferase α1, c-Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans(‡).1 passage
• Deregulated neddylation in liver fibrosis.1 passage
• Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis.1 passage
• Designing Clinical Trials in Wilson's Disease.1 passage
• Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.1 passage
• Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications.1 passage
• Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease.1 passage
• Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C.1 passage
• Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The royal free hospital cirrhosis glomerular filtration rate.1 passage
• Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.1 passage
• Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.1 passage
• Development of Capsular Fibrosis Beneath the Liver Surface in Humans and Mice.1 passage
• Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.1 passage
• Development of a novel frailty index to predict mortality in patients with end-stage liver disease.1 passage
• Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.1 passage
• Development of risk scoring system for stratifying population for hepatocellular carcinoma screening.1 passage
• Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.1 passage
• Diabetes and prediabetes in patients with hepatitis B residing in North America.1 passage
• Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People.1 passage
• Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies.1 passage
• Diagnosis and Treatment of Alcohol Use Disorder in Patients With End-Stage Alcoholic Liver Disease.1 passage
• Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time.1 passage
• Diagnostic Accuracy of Serum Matrix Metalloproteinase-7 for Biliary Atresia.1 passage
• Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease.1 passage
• Diagnostic and Prognostic Significance of Complement in Patients With Alcohol-Associated Hepatitis.1 passage
• Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.1 passage
• Diet Associations With Nonalcoholic Fatty Liver Disease in an Ethnically Diverse Population: The Multiethnic Cohort.1 passage
• Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort.1 passage
• Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice.1 passage
• Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A USA-Based Study.1 passage
• Dietary Patterns and Risk of Hepatocellular Carcinoma Among U.S. Men and Women.1 passage
• Differences in long-term survival among liver transplant recipients and the general population: a population-based Nordic study.1 passage
• Differential effects of targeting Notch receptors in a mouse model of liver cancer.1 passage
• Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.1 passage
• Differentiation of acute from chronic hepatitis C virus infection by nonstructural 5B deep sequencing: a population-level tool for incidence estimation.1 passage
• Differentiation therapy for hepatocellular carcinoma: Multifaceted effects of miR-148a on tumor growth and phenotype and liver fibrosis.1 passage
• Direct Inhibition of Hepatitis B e Antigen by Core Protein Allosteric Modulator.1 passage
• Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs.1 passage
• Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.1 passage
• Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.1 passage
• Discontinuation of oral antivirals in chronic hepatitis B: A systematic review.1 passage
• Discovery and Validation of a Biomarker Model (PRESERVE) Predictive of Renal Outcomes After Liver Transplantation.1 passage
• Discovery of a Carbamoyl Phosphate Synthetase 1-Deficient HCC Subtype With Therapeutic Potential Through Integrative Genomic and Experimental Analysis.1 passage
• Disruption of Renal Arginine Metabolism Promotes Kidney Injury in Hepatorenal Syndrome in Mice.1 passage
• Dissecting the role of epidermal growth factor receptor catalytic activity during liver regeneration and hepatocarcinogenesis.1 passage
• Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.1 passage
• Disulfide High-Mobility Group Box 1 Drives Ischemia-Reperfusion Injury in Human Liver Transplantation.1 passage
• Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.1 passage
• Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation.1 passage
• Double-negative feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1 regulates hepatocellular carcinoma tumor growth and metastasis.1 passage
• Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma.1 passage
• Down-regulation of hepatocyte nuclear factor-4α and defective zonation in livers expressing mutant Z α1-antitrypsin.1 passage
• Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.1 passage
• Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.1 passage
• Driving Nonalcoholic Steatohepatitis Forward Using the FibroScan Aspartate Aminotransferase Score, But Obey the Traffic Lights.1 passage
• Drug rechallenge following drug-induced liver injury.1 passage
• Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases.1 passage
• Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.1 passage
• Dual Specificity Phosphatase 12 Regulates Hepatic Lipid Metabolism Through Inhibition of the Lipogenesis and Apoptosis Signal-Regulating Kinase 1 Pathways.1 passage
• Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma.1 passage
• Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma.1 passage
• Dual role for inositol-requiring enzyme 1α in promoting the development of hepatocellular carcinoma during diet-induced obesity in mice.1 passage
• Dual-Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta-Activated Kinase 1 Suppression.1 passage
• Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.1 passage
• Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.1 passage
• Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis.1 passage
• Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.1 passage
• Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances.1 passage
• Dysregulated Autophagy and Lysosome Function Are Linked to Exosome Production by Micro-RNA 155 in Alcoholic Liver Disease.1 passage
• Dysregulated iron homeostasis is strongly associated with multiorgan failure and early mortality in acute-on-chronic liver failure.1 passage
• Dysregulated serum response factor triggers formation of hepatocellular carcinoma.1 passage
• Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.1 passage
• Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.1 passage
• E-cigarettes and Western Diet: Important Metabolic Risk Factors for Hepatic Diseases.1 passage
• E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.1 passage
• ER stress promotes HBV production by enhancing utilization of the autophagosome- multivesicular body axis.1 passage
• EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.1 passage
• Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.1 passage
• Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus-Positive Patients: Incidence and Associated Factors.1 passage
• Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.1 passage
• Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States.1 passage
• Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis.1 passage
• Economic and Health Care Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States.1 passage
• Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study.1 passage
• Effect of Increased Alcohol Consumption During COVID-19 Pandemic on Alcohol-related Liver Disease: A Modeling Study.1 passage
• Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.1 passage
• Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease.1 passage
• Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma.1 passage
• Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.1 passage
• Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.1 passage
• Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.1 passage
• Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.1 passage
• Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases.1 passage
• Effects of Endotoxin on Type 3 Inositol 1,4,5-Trisphosphate Receptor in Human Cholangiocytes.1 passage
• Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study.1 passage
• Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management.1 passage
• Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study.1 passage
• Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial.1 passage
• Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.1 passage
• Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma.1 passage
• Efficacy of Granulocyte Colony-stimulating Factor in the Management of Steroid-Nonresponsive Severe Alcoholic Hepatitis: A Double-Blind Randomized Controlled Trial.1 passage
• Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus.1 passage
• Efficient replication of blood-borne hepatitis C virus in human fetal liver stem cells.1 passage
• Efficiently Restored Thrombopoietin Production by Ashwell-Morell Receptor and IL-6R Induced Janus Kinase 2/Signal Transducer and Activator of Transcription Signaling Early After Partial Hepatectomy.1 passage
• Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.1 passage
• Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study.1 passage
• Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.1 passage
• Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure.1 passage
• Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study).1 passage
• Elevated Fructose and Uric Acid Through Aldose Reductase Contribute to Experimental and Human Alcoholic Liver Disease.1 passage
• Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.1 passage
• Emerging roles of Notch signaling in liver disease.1 passage
• Emerging trends in hepatocellular carcinoma incidence and mortality.1 passage
• Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.1 passage
• Endoplasmic Reticulum Stress Causes Liver Cancer Cells to Release Exosomal miR-23a-3p and Up-regulate Programmed Death Ligand 1 Expression in Macrophages.1 passage
• Endoscopic Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial.1 passage
• Endoscopic Ultrasound/Fine Needle Aspiration Is Effective for Lymph Node Staging in Patients With Cholangiocarcinoma.1 passage
• Endothelial Leukocyte Cell-Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulin-Like and Epidermal Growth Factor-Like Domains 1 Signaling in Liver Fibrosis.1 passage
• Endothelial p300 Promotes Portal Hypertension and Hepatic Fibrosis Through C-C Motif Chemokine Ligand 2-Mediated Angiocrine Signaling.1 passage
• Engaging hepatitis C infected patients in cost-effectiveness analyses: A literature review.1 passage
• Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.1 passage
• Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis.1 passage
• Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.1 passage
• Enhancing the Therapeutic Efficacy of PD-L1 Antibody for Metastasized Liver Cancer by Overcoming Hepatic Immunotolerance.1 passage
• Enhancing the functional maturity of induced pluripotent stem cell-derived human hepatocytes by controlled presentation of cell-cell interactions in vitro.1 passage
• Enoxacin Up-Regulates MicroRNA Biogenesis and Down-Regulates Cytotoxic CD8 T-Cell Function in Autoimmune Cholangitis.1 passage
• Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.1 passage
• Epidemiological Features of NAFLD From 1999 to 2018 in China.1 passage
• Epidemiology of Hepatocellular Carcinoma.1 passage
• Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B.1 passage
• Epigenome-Wide Analysis of Methylation Changes in the Sequence of Gallstone Disease, Dysplasia, and Gallbladder Cancer.1 passage
• Equitable Access to Liver Transplant: Bridging the Gaps in the Social Determinants of Health.1 passage
• Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis.1 passage
• Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.1 passage
• Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations.1 passage
• Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial.1 passage
• Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.1 passage
• Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013-2016.1 passage
• Estimation of hepatitis C virus infections resulting from vertical transmission in Egypt.1 passage
• Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2).1 passage
• European Liver Transplant Registry: donor and transplant surgery aspects of 16,641 liver transplantations in children.1 passage
• Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.1 passage
• Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.1 passage
• Evaluation of a Multifaceted Intervention to Reduce Health Disparities in Hepatitis C Screening: A Pre-Post Analysis.1 passage
• Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals.1 passage
• Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.1 passage
• Evolution of Systemic Therapy for Hepatocellular Carcinoma.1 passage
• Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.1 passage
• Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.1 passage
• Excretion of infectious hepatitis E virus into milk in cows imposes high risks of zoonosis.1 passage
• Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study.1 passage
• Exercise Training Decreases Hepatic Injury and Metastases Through Changes in Immune Response to Liver Ischemia/Reperfusion in Mice.1 passage
• Exome Sequencing in Clinical Hepatology.1 passage
• Exome sequencing in HFE C282Y homozygous men with extreme phenotypes identifies a GNPAT variant associated with severe iron overload.1 passage
• Exosomal Interferon-Induced Transmembrane Protein 2 Transmitted to Dendritic Cells Inhibits Interferon Alpha Pathway Activation and Blocks Anti-Hepatitis B Virus Efficacy of Exogenous Interferon Alpha.1 passage
• Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System.1 passage
• Exosome miR-335 as a novel therapeutic strategy in hepatocellular carcinoma.1 passage
• Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease.1 passage
• Expression of Metastatic Tumor Antigen 1 Splice Variant Correlates With Early Recurrence and Aggressive Features of Hepatitis B Virus-Associated Hepatocellular Carcinoma.1 passage
• Expression of microRNA-155 in inflammatory cells modulates liver injury.1 passage
• External Validation of a Pretransplant Biomarker Model (REVERSE) Predictive of Renal Recovery After Liver Transplantation.1 passage
• External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: A multicenter cohort study.1 passage
• Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells.1 passage
• Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model.1 passage
• Extracellular vesicles derived from mesenchymal stem/stromal cells: The regenerative impact in liver diseases.1 passage
• Extracellular vesicles in liver pathobiology: Small particles with big impact.1 passage
• Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood.1 passage
• Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.1 passage
• Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).1 passage
• FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.1 passage
• FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.1 passage
• FUN14 Domain-Containing 1-Mediated Mitophagy Suppresses Hepatocarcinogenesis by Inhibition of Inflammasome Activation in Mice.1 passage
• Factors Associated With Hepatitis A Mortality During Person-to-Person Outbreaks: A Matched Case-Control Study-United States, 2016-2019.1 passage
• Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.1 passage
• Farnesoid X Receptor Activation Impairs Liver Progenitor Cell-Mediated Liver Regeneration via the PTEN-PI3K-AKT-mTOR Axis in Zebrafish.1 passage
• Farnesoid X receptor ablation sensitizes mice to hepatitis b virus X protein-induced hepatocarcinogenesis.1 passage
• Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice.1 passage
• Fat-associated Lymphoid Clusters as Expandable Niches for Ectopic Liver Development.1 passage
• Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis.1 passage
• Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities.1 passage
• Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.1 passage
• Fatty acid desaturase 1 gene polymorphisms control human hepatic lipid composition.1 passage
• Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.1 passage
• Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.1 passage
• Fecal Microbiome Distinguishes Alcohol Consumption From Alcoholic Hepatitis But Does Not Discriminate Disease Severity.1 passage
• Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial.1 passage
• Fibrates and cholestasis.1 passage
• Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.1 passage
• Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?1 passage
• Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.1 passage
• Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.1 passage
• Financial Compensation For Hepatologists in Different Practice Settings.1 passage
• Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States.1 passage
• Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.1 passage
• First international external quality assessment for hepatitis delta virus RNA quantification in plasma.1 passage
• Five-year histological and serological follow-up of operationally tolerant pediatric liver transplant recipients enrolled in WISP-R.1 passage
• Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy.1 passage
• Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1.1 passage
• Fluorescent peptide highlights micronodules in murine hepatocellular carcinoma models and humans in vitro.1 passage
• Focal Adhesion Kinase and β-Catenin Cooperate to Induce Hepatocellular Carcinoma.1 passage
• Follistatin-controlled activin-HNF4α-coagulation factor axis in liver progenitor cells determines outcome of acute liver failure.1 passage
• Forkhead box A2 regulates biliary heterogeneity and senescence during cholestatic liver injury in mice‡.1 passage
• Four Biomarkers Linked to Activation of Cluster of Differentiation 8-Positive Lymphocytes Predict Clinical Outcomes in Pediatric Acute Liver Failure.1 passage
• Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma.1 passage
• FoxO3 inactivation promotes human cholangiocarcinoma tumorigenesis and chemoresistance through Keap1-Nrf2 signaling.1 passage
• Fractional excretion of urea: A simple tool for the differential diagnosis of acute kidney injury in cirrhosis.1 passage
• Frailty is associated with increased risk of cirrhosis disease progression and death.1 passage
• Frailty, Mortality, and Healthcare Utilization after Liver Transplantation: From the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study.1 passage
• Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patient-Reported Outcomes in Cirrhosis.1 passage
• Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r.1 passage
• From NAFLD to MAFLD: Implications of a Premature Change in Terminology.1 passage
• Fructose-1,6-Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis.1 passage
• Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.1 passage
• Functional Comparison of Interferon-α Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-α and Interferon-γ Signaling.1 passage
• Functional decline in patients with cirrhosis awaiting liver transplantation: Results from the functional assessment in liver transplantation (FrAILT) study.1 passage
• Functional defect of variants in the adenosine triphosphate-binding sites of ABCB4 and their rescue by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770).1 passage
• Functional lipidomics: Palmitic acid impairs hepatocellular carcinoma development by modulating membrane fluidity and glucose metabolism.1 passage
• GALAD Demonstrates High Sensitivity for HCC Surveillance in a Cohort of Patients with Cirrhosis.1 passage
• Galectin-9: Diverse roles in hepatic immune homeostasis and inflammation.1 passage
• Gallbladder Dyskinesia Is Associated With an Impaired Postprandial Fibroblast Growth Factor 19 Response in Critically Ill Patients.1 passage
• Gallstone Disease and Type 2 Diabetes Risk: A Mendelian Randomization Study.1 passage
• Gallstones, Body Mass Index, C-Reactive Protein, and Gallbladder Cancer: Mendelian Randomization Analysis of Chilean and European Genotype Data.1 passage
• Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway.1 passage
• Gene Deconvolution Reveals Aberrant Liver Regeneration and Immune Cell Infiltration in Alcohol-Associated Hepatitis.1 passage
• Gene-disease associations identify a connectome with shared molecular pathways in human cholangiopathies.1 passage
• Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome.1 passage
• Generation of pediatric liver cancer patient-derived xenograft platforms for pediatric liver cancer: A critical stage in the development of anticancer treatments.1 passage
• Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.1 passage
• Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology.1 passage
• Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers.1 passage
• Genetic Variation in the Mitochondrial Glycerol-3-Phosphate Acyltransferase Is Associated With Liver Injury.1 passage
• Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains.1 passage
• Genetic variants in five novel loci including CFB and CD40 predispose to chronic hepatitis B.1 passage
• Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B.1 passage
• Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.1 passage
• Genetics Meets Therapy? Exome-wide Association Study Reveals a Loss-of-Function Variant in 17-Beta-Hydroxysteroid Dehydrogenase 13 That Protects Patients From Liver Damage and Nonalcoholic Fatty Liver Disease Progression.1 passage
• Genome-wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis.1 passage
• Genome-wide association of individual vulnerability with alcohol-associated liver disease: A Korean genome and epidemiology study.1 passage
• Genome-wide association study in mice identifies loci affecting liver-related phenotypes including Sel1l influencing serum bile acids.1 passage
• Genomic Analysis of Vascular Invasion in HCC Reveals Molecular Drivers and Predictive Biomarkers.1 passage
• Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.1 passage
• Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups.1 passage
• Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.1 passage
• Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.1 passage
• Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.1 passage
• Ginsenoside Rg3 restores hepatitis C virus-induced aberrant mitochondrial dynamics and inhibits virus propagation.1 passage
• Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.1 passage
• Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.1 passage
• Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.1 passage
• Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.1 passage
• Glial Cell Line-Derived Neurotrophic Factor Enhances Autophagic Flux in Mouse and Rat Hepatocytes and Protects Against Palmitate Lipotoxicity.1 passage
• Global Burden of Non-alcoholic Fatty Liver Disease (NAFLD) and chronic liver disease (CLD) Among Adolescents and Young Adults.1 passage
• Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma.1 passage
• Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate.1 passage
• Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.1 passage
• Global distribution and prevalence of hepatitis C virus genotypes.1 passage
• Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.1 passage
• Global microRNA expression profiling in the liver biopsies of hepatitis B virus-infected patients suggests specific microRNA signatures for viral persistence and hepatocellular injury.1 passage
• Glucose-6-Phosphate Regulates Hepatic Bile Acid Synthesis in Mice.1 passage
• Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.1 passage
• Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma.1 passage
• Grade 1 Acute on Chronic Liver Failure Is a Predictor for Subsequent Grade 3 Failure.1 passage
• Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure.1 passage
• Group-2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2-Neutrophil-Induced Immunosuppression.1 passage
• Growth Hormone Stops Excessive Inflammation After Partial Hepatectomy, Allowing Liver Regeneration and Survival Through Induction of H2-Bl/HLA-G.1 passage
• Growth factor receptor binding protein 14 inhibition triggers insulin-induced mouse hepatocyte proliferation and is associated with hepatocellular carcinoma.1 passage
• Guanine Nucleotide-Binding Protein G(i) Subunit Alpha 2 Exacerbates NASH Progression by Regulating Peroxiredoxin 1-Related Inflammation and Lipophagy.1 passage
• Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.1 passage
• Gut Microbiome Features Associated with Liver Fibrosis in Hispanics, a Population at High Risk for Fatty Liver Disease.1 passage
• Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach.1 passage
• H19 Promotes HCC Bone Metastasis Through Reducing Osteoprotegerin Expression in a Protein Phosphatase 1 Catalytic Subunit Alpha/p38 Mitogen-Activated Protein Kinase-Dependent Manner and Sponging microRNA 200b-3p.1 passage
• H19 promotes cholestatic liver fibrosis by preventing ZEB1-mediated inhibition of epithelial cell adhesion molecule.1 passage
• HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska Study.1 passage
• HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy.1 passage
• HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC.1 passage
• HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.1 passage
• HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein.1 passage
• HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma.1 passage
• HLA-B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans.1 passage
• HLA-B*35:01 and Green Tea-Induced Liver Injury.1 passage
• HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.1 passage
• Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?1 passage
• Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.1 passage
• Heat Shock Protein 90α-Dependent B-Cell-2-Associated Transcription Factor 1 Promotes Hepatocellular Carcinoma Proliferation by Regulating MYC Proto-Oncogene c-MYC mRNA Stability.1 passage
• Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.1 passage
• Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis.1 passage
• Hepatic CREBZF couples insulin to lipogenesis by inhibiting insig activity and contributes to hepatic steatosis in diet-induced insulin-resistant mice.1 passage
• Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.1 passage
• Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis.1 passage
• Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.1 passage
• Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.1 passage
• Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma.1 passage
• Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3.1 passage
• Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor γ in Mice.1 passage
• Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis.1 passage
• Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH).1 passage
• Hepatic PPARα function is controlled by polyubiquitination and proteasome-mediated degradation through the coordinated actions of PAQR3 and HUWE1.1 passage
• Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta-Activated Kinase 1-c-Jun-N-Terminal Kinase/p38 Signaling.1 passage
• Hepatic gene transfer of human aquaporin-1 improves bile salt secretory failure in rats with estrogen-induced cholestasis.1 passage
• Hepatic inflammation and fibrosis: functional links and key pathways.1 passage
• Hepatic leukocyte immunoglobulin-like receptor B4 (LILRB4) attenuates nonalcoholic fatty liver disease via SHP1-TRAF6 pathway.1 passage
• Hepatic lipid droplet biology: Getting to the root of fatty liver.1 passage
• Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies.1 passage
• Hepatic stellate cell and monocyte interaction contributes to poor prognosis in hepatocellular carcinoma.1 passage
• Hepatic stellate cell-derived platelet-derived growth factor receptor-alpha-enriched extracellular vesicles promote liver fibrosis in mice through SHP2.1 passage
• Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination.1 passage
• Hepatic stellate cells relay inflammation signaling from sinusoids to parenchyma in mouse models of immune-mediated hepatitis.1 passage
• Hepatitis A hospitalizations in the United States, 2002-2011.1 passage
• Hepatitis B Virus DNA Polymerase Restrains Viral Replication Through the CREB1/HOXA Distal Transcript Antisense RNA Homeobox A13 Axis.1 passage
• Hepatitis B Virus Evasion From Cyclic Guanosine Monophosphate-Adenosine Monophosphate Synthase Sensing in Human Hepatocytes.1 passage
• Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes.1 passage
• Hepatitis B Virus Pregenomic RNA in Hepatocellular Carcinoma: A Nosological and Prognostic Determinant.1 passage
• Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection.1 passage
• Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination.1 passage
• Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma.1 passage
• Hepatitis B Virus-Upregulated LNC-HUR1 Promotes Cell Proliferation and Tumorigenesis by Blocking p53 Activity.1 passage
• Hepatitis B cure: From discovery to regulatory approval.1 passage
• Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity.1 passage
• Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis.1 passage
• Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.1 passage
• Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.1 passage
• Hepatitis B virus X protein-elevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis.1 passage
• Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages.1 passage
• Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.1 passage
• Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.1 passage
• Hepatitis B virus surface gene pre-S1 passage
• Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.1 passage
• Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.1 passage
• Hepatitis C Virus E2 Envelope Glycoprotein Induces an Immunoregulatory Phenotype in Macrophages.1 passage
• Hepatitis C Virus Manipulates Humans as its Favorite Host for a Long-Term Relationship.1 passage
• Hepatitis C Virus Mediated Inhibition of miR-181c Activates ATM Signaling and Promotes Hepatocyte Growth.1 passage
• Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience.1 passage
• Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.1 passage
• Hepatitis C transmission from seropositive, nonviremic donors to non-hepatitis C liver transplant recipients.1 passage
• Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs.1 passage
• Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study.1 passage
• Hepatitis C viral load, genotype, and increased risk of developing end-stage renal disease: REVEAL-HCV study.1 passage
• Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells.1 passage
• Hepatitis C virus drug resistance-associated substitutions: State of the art summary.1 passage
• Hepatitis C virus infection triggers a tumor-like glutamine metabolism.1 passage
• Hepatitis C virus infects rhesus macaque hepatocytes and simianized mice.1 passage
• Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study.1 passage
• Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trials.1 passage
• Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.1 passage
• Hepatitis C virus-induced CCL5 secretion from macrophages activates hepatic stellate cells.1 passage
• Hepatitis C virus-induced reduction in miR-181a impairs CD4(+) T-cell responses through overexpression of DUSP6.1 passage
• Hepatitis C virus-induced tumor-initiating cancer stem-like cells activate stromal fibroblasts in a xenograft tumor model.1 passage
• Hepatitis E Virus Infections Among Human Immunodeficiency Virus-Positive Individuals During an Outbreak of Acute Hepatitis A in Taiwan.1 passage
• Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable.1 passage
• HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk.1 passage
• Hepatobiliary Organoids and Their Applications for Studies of Liver Health and Disease: Are We There Yet?1 passage
• Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.1 passage
• Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.1 passage
• Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease.1 passage
• Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium.1 passage
• Hepatocellular Carcinoma-Associated Protein TD26 Interacts and Enhances Sterol Regulatory Element-Binding Protein 1 Activity to Promote Tumor Cell Proliferation and Growth.1 passage
• Hepatocellular carcinoma repression by TNFα-mediated synergistic lethal effect of mitosis defect-induced senescence and cell death sensitization.1 passage
• Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.1 passage
• Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system.1 passage
• Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver.1 passage
• Hepatocyte Nuclear Factor 4-Alpha Is Essential for the Active Epigenetic State at Enhancers in Mouse Liver.1 passage
• Hepatocyte Stress Increases Expression of Yes-Associated Protein and Transcriptional Coactivator With PDZ-Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis.1 passage
• Hepatocyte autotaxin expression promotes liver fibrosis and cancer.1 passage
• Hepatocyte buds derived from progenitor cells repopulate regions of parenchymal extinction in human cirrhosis.1 passage
• Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis.1 passage
• Hepatocyte mitochondrial DNA released in microparticles and toll-like receptor 9 activation: A link between lipotoxicity and inflammation during nonalcoholic steatohepatitis.1 passage
• Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during hepatitis C virus infection.1 passage
• Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice.1 passage
• Hepatocytes and neutrophils cooperatively suppress bacterial infection by differentially regulating lipocalin-2 and neutrophil extracellular traps.1 passage
• Hepatology in a changing health care landscape: A call for health services research.1 passage
• Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins.1 passage
• Hepatostat: Liver regeneration and normal liver tissue maintenance.1 passage
• Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.1 passage
• Hexa Histidine-Tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.1 passage
• High Mobility Group Box 1 Release by Cholangiocytes Governs Biliary Atresia Pathogenesis and Correlates With Increases in Afflicted Infants.1 passage
• High Mobility Group Box-1 Drives Fibrosis Progression Signaling via the Receptor for Advanced Glycation End Products in Mice.1 passage
• High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.1 passage
• High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center.1 passage
• High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers.1 passage
• High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis.1 passage
• High priority for hepatitis C screening in safety net hospitals: Results from a prospective cohort of 4582 hospitalized baby boomers.1 passage
• High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires.1 passage
• Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments.1 passage
• Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf/Cip1) stabilization by activating the ERK1/2-MAPK pathway.1 passage
• Histidine-rich glycoprotein promotes macrophage activation and inflammation in chronic liver disease.1 passage
• Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients.1 passage
• Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1.1 passage
• Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States.1 passage
• Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.1 passage
• How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool.1 passage
• How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.1 passage
• Human Antigen R (HuR): A Regulator of Heme Oxygenase-1 Cytoprotection in Mouse and Human Liver Transplant Injury.1 passage
• Human CD96 Correlates to Natural Killer Cell Exhaustion and Predicts the Prognosis of Human Hepatocellular Carcinoma.1 passage
• Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells.1 passage
• Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.1 passage
• Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury.1 passage
• Human Leukocyte Antigen F Locus Adjacent Transcript 10 Overexpression Disturbs WISP1 Protein and mRNA Expression to Promote Hepatocellular Carcinoma Progression.1 passage
• Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.1 passage
• Human embryonic stem cell-derived hepatoblasts are an optimal lineage stage for hepatitis C virus infection.1 passage
• Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection.1 passage
• Human immunodeficiency virus and liver disease: An update.1 passage
• Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma.1 passage
• Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.1 passage
• Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis.1 passage
• Human keratin 8 variants promote mouse acetaminophen hepatotoxicity coupled with c-jun amino-terminal kinase activation and protein adduct formation.1 passage
• Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.1 passage
• Human liver sinusoidal endothelial cells promote intracellular crawling of lymphocytes during recruitment: A new step in migration.1 passage
• Human macrophage ferroportin biology and the basis for the ferroportin disease.1 passage
• Hydrogen Sulfide Alleviates Liver Injury Through the S-Sulfhydrated-Kelch-Like ECH-Associated Protein 1/Nuclear Erythroid 2-Related Factor 2/Low-Density Lipoprotein Receptor-Related Protein 1 Pathway.1 passage
• Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis.1 passage
• Hyperpolarized Metabolic Imaging Detects Latent Hepatocellular Carcinoma Domains Surviving Locoregional Therapy.1 passage
• Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.1 passage
• Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26.1 passage
• Hypoxia mediates mitochondrial biogenesis in hepatocellular carcinoma to promote tumor growth through HMGB1 and TLR9 interaction.1 passage
• Hypoxia-Inducible Exosomes Facilitate Liver-Tropic Premetastatic Niche in Colorectal Cancer.1 passage
• Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence.1 passage
• Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein.1 passage
• Hypoxia-inducible factor-1α/interleukin-1β signaling enhances hepatoma epithelial-mesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment.1 passage
• ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma.1 passage
• IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.1 passage
• IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections.1 passage
• IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism.1 passage
• IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.1 passage
• IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition1 passage
• Identification and Replication of Six Loci Associated With Gallstone Disease.1 passage
• Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Type-A Receptor 5 Kinases in Hepatocellular Carcinoma.1 passage
• Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.1 passage
• Identification of Polycystic Kidney Disease 1 Like 1 Gene Variants in Children With Biliary Atresia Splenic Malformation Syndrome.1 passage
• Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis.1 passage
• Identification of a Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma.1 passage
• Identification of a mitochondrial defect gene signature reveals NUPR1 as a key regulator of liver cancer progression.1 passage
• Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma.1 passage
• Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.1 passage
• Identification of p38 MAPK and JNK as new targets for correction of Wilson disease-causing ATP7B mutants.1 passage
• Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.1 passage
• Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.1 passage
• Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis.1 passage
• Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.1 passage
• Idiopathic Portal Hypertension.1 passage
• Imaging for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.1 passage
• Immune Activation Induces Telomeric DNA Damage and Promotes Short-Lived Effector T Cell Differentiation in Chronic HCV Infection.1 passage
• Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.1 passage
• Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.1 passage
• Immune-Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B-Infected Cells.1 passage
• Immune-Responsive Gene 1/Itaconate Activates Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocytes to Protect Against Liver Ischemia-Reperfusion Injury.1 passage
• Immuno-vascular Classification of HCC Reflects Reciprocal Interaction between Immune and Angiogenic Tumor Microenvironments.1 passage
• Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.1 passage
• Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.1 passage
• Immunomodulation and RNA interference alter Hepatitis B Virus-specific CD8 T cell recognition of infected HepG2-NTCP.1 passage
• Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.1 passage
• Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection.1 passage
• Immunosuppression Minimization Trials in Liver Transplantation: Can We Predict Humoral Response to Assess Eligibility?1 passage
• Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus.1 passage
• Immunosuppressive Drug-Resistant Armored T-Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant Patients.1 passage
• Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines.1 passage
• Impact of Alcohol Use Disorder Treatment on Clinical Outcomes Among Patients With Cirrhosis.1 passage
• Impact of All-Oral Direct-Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States.1 passage
• Impact of COVID-19 Pandemic on Liver Transplantation and Alcohol-Associated Liver Disease in the USA.1 passage
• Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.1 passage
• Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.1 passage
• Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C.1 passage
• Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study.1 passage
• Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease.1 passage
• Impact of an electronic health record alert in primary care on increasing hepatitis c screening and curative treatment for baby boomers.1 passage
• Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study.1 passage
• Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation.1 passage
• Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.1 passage
• Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis.1 passage
• Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma.1 passage
• Impaired Bile Secretion Promotes Hepatobiliary Injury in Sickle Cell Disease.1 passage
• Impaired Chylomicron Assembly Modifies Hepatic Metabolism Through Bile Acid-Dependent and Transmissible Microbial Adaptations.1 passage
• Impaired monocyte-macrophage functions and defective Toll-like receptor signaling in hepatitis E virus-infected pregnant women with acute liver failure.1 passage
• Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.1 passage
• Improved posttransplant mortality after share 35 for liver transplantation.1 passage
• Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data.1 passage
• Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.1 passage
• Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.1 passage
• In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood.1 passage
• In autoimmune hepatitis type 1 or the autoimmune hepatitis-sclerosing cholangitis variant defective regulatory T-cell responsiveness to IL-2 results in low IL-10 production and impaired suppression.1 passage
• In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.1 passage
• Inadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver Disease.1 passage
• Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis.1 passage
• Incidence and Prediction of HBsAg Seroconversion in a Prospective Multi-ethnic HBeAg-Negative Chronic Hepatitis B Cohort.1 passage
• Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B.1 passage
• Incidence, Risk Factors, and Outcomes of Transition of Acute Kidney Injury to Chronic Kidney Disease in Cirrhosis: A Prospective Cohort Study.1 passage
• Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis.1 passage
• Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality.1 passage
• Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD.1 passage
• Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis.1 passage
• Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3.1 passage
• Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis.1 passage
• Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.1 passage
• Increasing Utilization and Excellent Initial Outcomes Following Liver Transplant of Hepatitis C Virus (HCV)-Viremic Donors Into HCV-Negative Recipients: Outcomes Following Liver Transplant of HCV-Viremic Donors.1 passage
• Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population.1 passage
• Indeterminate pediatric acute liver failure is uniquely characterized by a CD1031 passage
• Indole Alleviates Diet-Induced Hepatic Steatosis and Inflammation in a Manner Involving Myeloid Cell 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3.1 passage
• Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.1 passage
• Induced pluripotent stem cells model personalized variations in liver disease resulting from α1-antitrypsin deficiency.1 passage
• Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma.1 passage
• Induction of cancer cell stemness by depletion of macrohistone H2A1 in hepatocellular carcinoma.1 passage
• Inflammation and Microbiota Fingerprint: Delphi's Oracle for Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma?1 passage
• Inflammation-Induced Long Intergenic Noncoding RNA (LINC00665) Increases Malignancy Through Activating the Double-Stranded RNA-Activated Protein Kinase/Nuclear Factor Kappa B Pathway in Hepatocellular Carcinoma.1 passage
• Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort).1 passage
• Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.1 passage
• Inhibition of Long Noncoding RNA Linc-Pint by Hepatitis C Virus in Infected Hepatocytes Enhances Lipogenesis.1 passage
• Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.1 passage
• Insights From Liver-Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR-Agonist Pharmacodynamics in Humans.1 passage
• Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.1 passage
• Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism.1 passage
• Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma.1 passage
• Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC.1 passage
• Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.1 passage
• Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.1 passage
• Integrin αvβ6 critically regulates hepatic progenitor cell function and promotes ductular reaction, fibrosis, and tumorigenesis.1 passage
• Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer.1 passage
• Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population.1 passage
• Interaction of tetraspan(in) TM4SF5 with CD44 promotes self-renewal and circulating capacities of hepatocarcinoma cells.1 passage
• Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.1 passage
• Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.1 passage
• Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease.1 passage
• Interferon regulatory factor 1-Rab27a regulated extracellular vesicles promote liver ischemia/reperfusion injury.1 passage
• Interferon-Induced Transmembrane Proteins Mediate Viral Evasion in Acute and Chronic Hepatitis C Virus Infection.1 passage
• Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation.1 passage
• Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.1 passage
• Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.1 passage
• Interleukin-1β/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis.1 passage
• Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis.1 passage
• Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.1 passage
• Intestinal Microbiome-Macrophage Crosstalk Contributes to Cholestatic Liver Disease by Promoting Intestinal Permeability in Mice.1 passage
• Intestinal Microbiota Mediates the Susceptibility to Polymicrobial Sepsis-Induced Liver Injury by Granisetron Generation in Mice.1 passage
• Intestinal Virome in Patients With Alcoholic Hepatitis.1 passage
• Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances.1 passage
• Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.1 passage
• Intratumoral γδ T-Cell Infiltrates, Chemokine (C-C Motif) Ligand 4/Chemokine (C-C Motif) Ligand 5 Protein Expression and Survival in Patients With Hepatocellular Carcinoma.1 passage
• Involvement of TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With Liver Echinococcus multilocularis Infection.1 passage
• Iron Chaperone Poly rC Binding Protein 1 Protects Mouse Liver From Lipid Peroxidation and Steatosis.1 passage
• Is It Time to Consider Gut Microbiome Readouts for Precision Diagnosis and Treatment of Alcoholic Liver Disease?1 passage
• Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation?1 passage
• Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart.1 passage
• Is hepatitis E virus an emerging problem in industrialized countries?1 passage
• Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.1 passage
• Is mIndy a mediator of energy metabolism reprogramming in hepatocellular carcinoma induced by interleukin-6/signal transducer and activator of transcription 3 signaling?1 passage
• Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review.1 passage
• Is the regulatory effect of PCAF and sirtuin 7 on phosphoglycerate kinase 1 acetylation a universal mechanism underlying hepatocellular carcinoma progression?1 passage
• Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation.1 passage
• JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1.1 passage
• Jagged1 heterozygosity in mice results in a congenital cholangiopathy which is reversed by concomitant deletion of one copy of Poglut1 (Rumi).1 passage
• Keratin 23 Is a Peroxisome Proliferator-Activated Receptor Alpha-Dependent, MYC-Amplified Oncogene That Promotes Hepatocyte Proliferation.1 passage
• Keratins: Biomarkers and modulators of apoptotic and necrotic cell death in the liver.1 passage
• Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine.1 passage
• Khat chewing increases the risk for developing chronic liver disease: A hospital-based case-control study.1 passage
• Kidney transplant recipients with hepatitis C virus experienced 100% sustained virologic response at 12 weeks when treated with sofosbuvir-ledipasvir.1 passage
• Knockout of the primary sclerosing cholangitis-risk gene Fut2 causes liver disease in mice.1 passage
• L-ornithine L-aspartate in bouts of overt hepatic encephalopathy.1 passage
• LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions.1 passage
• LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC.1 passage
• LXRα Promotes Hepatosteatosis in Part Through Activation of MicroRNA-378 Transcription and Inhibition of Ppargc1β Expression.1 passage
• Laboratory of genetics and physiology 2 (LGP2) plays an essential role in hepatitis C virus infection-induced interferon responses.1 passage
• Lactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study.1 passage
• Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification.1 passage
• Large-Scale Production of LGR5-Positive Bipotential Human Liver Stem Cells.1 passage
• Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis.1 passage
• Large-scale computational models of liver metabolism: How far from the clinics?1 passage
• Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention.1 passage
• Late hepatitis B reactivation following direct-acting antiviral-based treatment of recurrent hepatitis C in an anti-HBc-positive liver transplant recipient.1 passage
• Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.1 passage
• Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma.1 passage
• Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis.1 passage
• Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.1 passage
• Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C.1 passage
• Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens.1 passage
• Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.1 passage
• Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis.1 passage
• Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.1 passage
• Letter to Editor: Locoregional Therapy Before Liver Transplantation for Hepatocellular Carcinoma.1 passage
• Letter to Editor: Response to AASLD Editorial/Message from the President.1 passage
• Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.1 passage
• Letter to Editor: Using Proper Methods to Identify Patients With Cirrhosis in Administrative Databases Is Crucial to Correctly Predict Outcomes.1 passage
• Letter to the Editor: A Prognostic Algorithm Based on Stage of Cirrhosis and Hepatic Venous Pressure Gradient to Improve Risk Stratification After Variceal Bleeding.1 passage
• Letter to the Editor: Abdominal Surgery in Idiopathic Noncirrhotic Portal Hypertension: Is Preemptive TIPS Reducing Postoperative Complications?1 passage
• Letter to the Editor: Age at Hepatitis B e Antigen Seroconversion and Other Factors for Outcomes of Chronic Hepatitis B.1 passage
• Letter to the Editor: Coinfection of Human Immunodeficiency Virus With Hepatitis C Virus: A Change of Paradigm.1 passage
• Letter to the Editor: Comment on Alpha-Fetoprotein Decrease From >1,000 to <500 ng/mL in Patients With Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.1 passage
• Letter to the Editor: Concerns Regarding the ACLF Research Consortium (AARC) Study on Corticosteroid Therapy for Autoimmune Hepatitis Flare Causing Acute on Chronic Liver Failure.1 passage
• Letter to the Editor: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in Patients With Nonalcoholic Fatty Liver Disease.1 passage
• Letter to the Editor: Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy.1 passage
• Letter to the Editor: Growth Hormone Stops Excessive Inflammation After Partial Hepatectomy, Allowing Liver Regeneration and Survival by Induction of H2-Bl/HLA-G.1 passage
• Letter to the Editor: Hepatic Resection Compared to Chemoembolization in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Comment For Moving Forward.1 passage
• Letter to the Editor: Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Steatohepatitis Cirrhosis and Diabetes: Insufficient for Individual Management.1 passage
• Letter to the Editor: Intrahepatic Lipid Content After Insulin Glargine Addition to Metformin in Type II Diabetes Mellitus With Nonalcoholic Fatty Liver Disease.1 passage
• Letter to the Editor: New kid in the playground: HBcrAg and risk of HCC.1 passage
• Letter to the Editor: Preemptive TIPS Must Be the Treatment of Choice for Child-Pugh Class C Patients With Variceal Bleeding?1 passage
• Letter to the Editor: Protein Disulfide Isomerase Family A Member 3 Pseudogene 1 Level Could Predict Recurrence-Free Survival in Hepatocellular Carcinoma: Reliable?1 passage
• Letter to the Editor: Re: Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.1 passage
• Letter to the Editor: Relevance of Circulating Extracellular Vesicles Carrying Sphingolipid Cargo in Alcoholic Hepatitis: Need for More Validation!1 passage
• Letter to the Editor: Role of Sorafenib in Liver Transplantation Outcomes of Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria?1 passage
• Letter to the Editor: Sodium-Glucose Cotransporter-2 Inhibitors Are Not the Magic Pills for Control of Ascites in Cirrhosis and Diabetes.1 passage
• Letter to the Editor: Statin Reduces the Risk of Hepatocellular Carcinoma Development in Patients With CHB.1 passage
• Letter to the Editor: Statins and Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.1 passage
• Letter to the Editor: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.1 passage
• Letter to the Editor: The Association Between Diabetes and Hepatocellular Carcinoma in Patients With Cirrhosis Caused by Nonalcoholic Fatty Liver Disease.1 passage
• Letter to the Editor: Tuberculosis and Antituberculosis Treatments Cannot Be Ignored When Evaluating Patients With Cirrhosis Who Are Coinfected With HIV or Not.1 passage
• Letter to the Editor: mTOR-Inhibitor-Based Immunosuppression Following Liver Transplantation for Hereditary Hemorrhagic Telangiectasia.1 passage
• Letter to the Editor: standardization of HBV RNA assay for the different phases of chronic hepatitis B is essential.1 passage
• Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination.1 passage
• Lettter to the editor on "Autoimmune hepatitis after COVID-19 vaccination".1 passage
• Leukocyte-specific protein 1: a novel regulator of hepatocellular proliferation and migration deleted in human hepatocellular carcinoma.1 passage
• Light Chain Deposition Disease: An Unusual Cause of Portal Hypertension.1 passage
• Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.1 passage
• Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma.1 passage
• Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease.1 passage
• Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data.1 passage
• Lipopolysaccharide Reverses Hepatic Stellate Cell Activation Through Modulation of cMyb, Small Mothers Against Decapentaplegic, and CCAAT/Enhancer-Binding Protein C/EBP Transcription Factors.1 passage
• Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis.1 passage
• Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation.1 passage
• Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.1 passage
• Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals.1 passage
• Liver Biochemistries in Hospitalized Patients With COVID-19.1 passage
• Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).1 passage
• Liver Disease and Coronavirus Disease 2019: From Pathogenesis to Clinical Care.1 passage
• Liver Diseases in the Perinatal Period: Interactions Between Mother and Infant.1 passage
• Liver Fat and Cardiometabolic Risk Factors Among School-Age Children.1 passage
• Liver Injury and Failure in Critical Illness.1 passage
• Liver Injury in Liver Transplant Recipients With Coronavirus Disease 2019 (COVID-19): U.S. Multicenter Experience.1 passage
• Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System.1 passage
• Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation.1 passage
• Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension-The Devil Is in the Details.1 passage
• Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension.1 passage
• Liver Transplant Listing in Pediatric Acute Liver Failure: Practices and Participant Characteristics.1 passage
• Liver Transplantation Following Yttrium-90 Radioembolization: 15-Year Experience in 207-Patient Cohort.1 passage
• Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.1 passage
• Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?1 passage
• Liver Transplantation in Unauthorized Immigrants in the United States.1 passage
• Liver X Receptor Alpha Activation Inhibits Autophagy and Lipophagy in Hepatocytes by Dysregulating Autophagy-Related 4B Cysteine Peptidase and Rab-8B, Reducing Mitochondrial Fuel Oxidation.1 passage
• Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation.1 passage
• Liver fibrosis scores predict liver disease mortality in the United States population.1 passage
• Liver injury from herbal and dietary supplements.1 passage
• Liver mortality attributable to chronic hepatitis C virus infection in Denmark and Scotland--using spontaneous resolvers as the benchmark comparator.1 passage
• Liver protects metastatic prostate cancer from induced death by activating E-cadherin signaling.1 passage
• Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey.1 passage
• Liver sinusoidal endothelial cells in hepatic fibrosis.1 passage
• Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy.1 passage
• Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.1 passage
• Lnc-UCID Promotes G1/S Transition and Hepatoma Growth by Preventing DHX9-Mediated CDK6 Down-regulation.1 passage
• Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats.1 passage
• Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia.1 passage
• Long Noncoding RNA p53-Stabilizing and Activating RNA Promotes p53 Signaling by Inhibiting Heterogeneous Nuclear Ribonucleoprotein K deSUMOylation and Suppresses Hepatocellular Carcinoma.1 passage
• Long noncoding RNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis.1 passage
• Long noncoding RNA HULC modulates the phosphorylation of YB-1 through serving as a scaffold of extracellular signal-regulated kinase and YB-1 to enhance hepatocarcinogenesis.1 passage
• Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay.1 passage
• Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin-6/STAT3 signaling pathway.1 passage
• Long-Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor-Specific Isoforms.1 passage
• Long-Term Outcomes After Transcatheter and Surgical Aortic Valve Replacement in Patients With Cirrhosis: A Guide for the Hepatologist.1 passage
• Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents.1 passage
• Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes.1 passage
• Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.1 passage
• Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study.1 passage
• Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.1 passage
• Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis.1 passage
• Long-term outcome in liver transplantation candidates with portopulmonary hypertension.1 passage
• Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.1 passage
• Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years.1 passage
• Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy.1 passage
• Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects.1 passage
• Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma.1 passage
• Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China.1 passage
• Lorcaserin Use in the Management of Morbid Obesity in a Pre-Liver Transplant Patient.1 passage
• Loss of Xanthine Oxidoreductase Potentiates Propagation of Hepatocellular Carcinoma Stem Cells.1 passage
• Loss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability.1 passage
• Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.1 passage
• Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy.1 passage
• Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis.1 passage
• Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness.1 passage
• Low Serum Hepcidin Is Associated With Reduced Short-Term Survival in Adults With Acute Liver Failure.1 passage
• Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.1 passage
• Low-grade endotoxemia and platelet activation in cirrhosis.1 passage
• Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment.1 passage
• Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).1 passage
• Lymphocyte Antigen 6 Complex, Locus C1 passage
• Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.1 passage
• Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis.1 passage
• M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring α1 passage
• MAF1 suppresses AKT-mTOR signaling and liver cancer through activation of PTEN transcription.1 passage
• MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis.1 passage
• MAIT cell tumor infiltration predicts long-term survival in cholangiocarcinoma.1 passage
• MAIT cells are chronically activated in patients with autoimmune liver disease and promote profibrogenic hepatic stellate cell activation.1 passage
• MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting List.1 passage
• MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma.1 passage
• MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology.1 passage
• METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N1 passage
• MRE for Prediction of Long-Term Progression and Outcome in Chronic Liver Disease: A Retrospective Study.1 passage
• MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-related fibrosis.1 passage
• MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).1 passage
• MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes.1 passage
• MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression.1 passage
• MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease.1 passage
• Macrophage nuclear factor erythroid 2-related factor 2 deficiency promotes innate immune activation by tissue inhibitor of metalloproteinase 3-mediated RhoA/ROCK pathway in the ischemic liver.1 passage
• Macrophage-derived vascular endothelial growth factor and angiogenesis within the hepatic scar-new pathways unmasked in the resolution of fibrosis.1 passage
• Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance.1 passage
• Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.1 passage
• Magnetic resonance elastography is superior to acoustic radiation force impulse for the Diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: A prospective study.1 passage
• Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease.1 passage
• Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.1 passage
• Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial.1 passage
• Main drivers of outcome differ between short term and long term in severe alcoholic hepatitis: A prospective study.1 passage
• Maintaining Patient Safety and Data Integrity of Nonalcoholic Steatohepatitis Clinical Trials During the Severe Acute Respiratory Syndrome-Coronavirus 2 Pandemic.1 passage
• Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity.1 passage
• Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis.1 passage
• Management of Sepsis in Patients With Cirrhosis: Current Evidence and Practical Approach.1 passage
• Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans.1 passage
• Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.1 passage
• Mast Cells Promote Nonalcoholic Fatty Liver Disease Phenotypes and Microvesicular Steatosis in Mice Fed a Western Diet.1 passage
• Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.1 passage
• Mast Cells in Liver Disease Progression: An Update on Current Studies and Implications.1 passage
• Maternal Early-Pregnancy Glucose Concentrations and Liver Fat Among School-Age Children.1 passage
• Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis.1 passage
• Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors.1 passage
• Mechanistic target of rapamycin complex 1 is an essential mediator of metabolic and mitogenic effects of fibroblast growth factor 19 in hepatoma cells.1 passage
• Medicaid Policy and Liver Transplant for Alcohol-Associated Liver Disease.1 passage
• Melanoma-Differentiation-Associated gene 5 protects against nonalcoholic steatohepatitis in mice.1 passage
• Menopausal hormone therapy and risk of biliary tract cancers.1 passage
• Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-κB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.1 passage
• Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings From a Multiethnic Cohort.1 passage
• Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients.1 passage
• Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.1 passage
• Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis.1 passage
• Metabolic dysfunction associated fatty liver disease improves detection of high liver stiffness: The rotterdam study.1 passage
• Metabolic profiling of fatty liver in young and middle-aged adults: Cross-sectional and prospective analyses of the Young Finns Study.1 passage
• Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B.1 passage
• Metabolism-induced tumor activator 1 (MITA1), an Energy Stress-Inducible Long Noncoding RNA, Promotes Hepatocellular Carcinoma Metastasis.1 passage
• Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.1 passage
• Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients.1 passage
• Methionine Adenosyltransferase α1 Is Targeted to the Mitochondrial Matrix and Interacts with Cytochrome P450 2E1 to Lower Its Expression.1 passage
• Methyl-Sensing Nuclear Receptor Liver Receptor Homolog-1 Regulates Mitochondrial Function in Mouse Hepatocytes.1 passage
• MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.1 passage
• MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer.1 passage
• MicroRNA (miR)-433 and miR-22 dysregulations induce histone-deacetylase-6 overexpression and ciliary loss in cholangiocarcinoma.1 passage
• MicroRNA Sequencing Identifies a Serum MicroRNA Panel, Which Combined With Aspartate Aminotransferase to Platelet Ratio Index Can Detect and Monitor Liver Disease in Pediatric Cystic Fibrosis.1 passage
• MicroRNA-125b attenuates epithelial-mesenchymal transitions and targets stem-like liver cancer cells through small mothers against decapentaplegic 2 and 4.1 passage
• MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.1 passage
• MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.1 passage
• MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis.1 passage
• MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice.1 passage
• MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.1 passage
• MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors.1 passage
• MicroRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation.1 passage
• Microbial-derived lithocholic acid and vitamin K2 drive the metabolic maturation of pluripotent stem cells-derived and fetal hepatocytes.1 passage
• Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults.1 passage
• Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.1 passage
• Milk Fat Globule-Epidermal Growth Factor-Factor 8 Improves Hepatic Steatosis and Inflammation.1 passage
• Mineralocorticoid receptor suppresses cancer progression and the Warburg effect by modulating the miR-338-3p-PKLR axis in hepatocellular carcinoma.1 passage
• Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus.1 passage
• Mitochondrial bioenergetics boost macrophages activation promoting liver regeneration in metabolically compromised animals.1 passage
• Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.1 passage
• Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-on-Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival.1 passage
• Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes.1 passage
• Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B.1 passage
• Model for End-Stage Liver Disease-Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease.1 passage
• Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing.1 passage
• Modeling Progress Toward Elimination of Hepatitis B in Australia.1 passage
• Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus/piggyBac transposase gene delivery system.1 passage
• Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.1 passage
• Modeling the Hepatology Workforce in the United States: A Predicted Critical Shortage.1 passage
• Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices.1 passage
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.1 passage
• Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study.1 passage
• Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.1 passage
• Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.1 passage
• Modulation of the Tryptophan Hydroxylase 1/Monoamine Oxidase-A/5-Hydroxytryptamine/5-Hydroxytryptamine Receptor 2A/2B/2C Axis Regulates Biliary Proliferation and Liver Fibrosis During Cholestasis.1 passage
• Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.1 passage
• Molecular Targets in Cholangiocarcinoma.1 passage
• Molecular pathophysiology of portal hypertension.1 passage
• Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.1 passage
• Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.1 passage
• Monocyte Chemoattractant Protein-Induced Protein 1 Targets Hypoxia-Inducible Factor 1α to Protect Against Hepatic Ischemia/Reperfusion Injury.1 passage
• Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).1 passage
• Monocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC).1 passage
• Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial.1 passage
• Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation.1 passage
• Mucosal-Associated Invariant T Cell Dysregulation Correlates With Conjugated Bilirubin Level in Chronic HBV Infection.1 passage
• Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.1 passage
• Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.1 passage
• Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis.1 passage
• Multicenter prospective validation of the Baveno IV and Baveno II/III criteria in cirrhosis patients with variceal bleeding.1 passage
• Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma.1 passage
• Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis.1 passage
• Mutational Signature Analysis Reveals Widespread Contribution of Pyrrolizidine Alkaloid Exposure to Human Liver Cancer.1 passage
• Mutations in the V-ATPase Assembly Factor VMA21 Cause a Congenital Disorder of Glycosylation With Autophagic Liver Disease.1 passage
• Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.1 passage
• Myeloid cells in hepatocellular carcinoma.1 passage
• Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis.1 passage
• N1 passage
• N-Acetylgalactosaminyltransferase-4 protects against hepatic ischaemia/reperfusion injury via blocking ASK1 N-terminal dimerization.1 passage
• N-Terminal PreS1 Sequence Regulates Efficient Infection of Cell-Culture-Generated Hepatitis B Virus.1 passage
• N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway.1 passage
• NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis.1 passage
• NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.1 passage
• NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040.1 passage
• NAFLD: Reporting Histologic Findings in Clinical Practice.1 passage
• NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH.1 passage
• NF-κB Regulation of LRH-1 and ABCG5/8 Potentiates Phytosterol Role in the Pathogenesis of Parenteral Nutrition-Associated Cholestasis.1 passage
• NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.1 passage
• NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer.1 passage
• National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.1 passage
• Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis.1 passage
• Natural immunoglobulin M initiates an inflammatory response important for both hepatic ischemia reperfusion injury and regeneration in mice.1 passage
• Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B.1 passage
• Natural killer cells regulate T cell immune responses in primary biliary cirrhosis.1 passage
• Near-Infrared Spectroscopy Reveals Brain Hypoxia and Cerebrovascular Dysregulation in Primary Biliary Cholangitis.1 passage
• Negative Regulation of Mitochondrial Antiviral Signaling Protein-Mediated Antiviral Signaling by the Mitochondrial Protein LRPPRC During Hepatitis C Virus Infection.1 passage
• Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis.1 passage
• Neurodegeneration in Hepatic and Neurologic Wilson's Disease.1 passage
• Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study.1 passage
• Neutrophil extracellular traps promote inflammation and development of hepatocellular carcinoma in nonalcoholic steatohepatitis.1 passage
• Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2-dependent angiogenesis in mice.1 passage
• New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.1 passage
• New Insights Into Intestinal Failure-Associated Liver Disease in Children.1 passage
• New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment.1 passage
• New insights into diagnosis and therapeutic options for proliferative hepatoblastoma.1 passage
• New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases.1 passage
• New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ-glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage.1 passage
• New therapeutic concepts in bile acid transport and signaling for management of cholestasis.1 passage
• Next-Generation Immunosequencing Reveals Pathological T-Cell Architecture in Autoimmune Hepatitis.1 passage
• Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.1 passage
• Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).1 passage
• Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis.1 passage
• Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B.1 passage
• Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor.1 passage
• Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic.1 passage
• Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study.1 passage
• Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists.1 passage
• Noncirrhotic complete obliterative portal vein thrombosis: Novel management using trans-splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization.1 passage
• Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study.1 passage
• Nonhospice Palliative Care Within the Treatment of End-Stage Liver Disease.1 passage
• Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease.1 passage
• Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.1 passage
• Noninvasive Tests of Liver Fibrosis and Their Combination in Nonalcoholic Fatty Liver Disease: From Selected Patients to Real-Life Populations.1 passage
• Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.1 passage
• Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.1 passage
• Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study.1 passage
• Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.1 passage
• Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus.1 passage
• Nonphagocytic Activation of NOX2 Is Implicated in Progressive Nonalcoholic Steatohepatitis During Aging.1 passage
• Nonselective β-blockers do not affect mortality in cirrhosis patients with ascites: Post Hoc analysis of three randomized controlled trials with 1198 patients.1 passage
• Nonstructural protein 5B promotes degradation of the NORE1A tumor suppressor to facilitate hepatitis C virus replication.1 passage
• Normothermic Machine Perfusion (NMP) Inhibits Proinflammatory Responses in the Liver and Promotes Regeneration.1 passage
• Nosocomial hepatitis C virus transmission from tampering with injectable anesthetic opioids.1 passage
• Novel educational interventions in residency increase knowledge of chronic liver disease and career interest in hepatology.1 passage
• Novel insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study.1 passage
• Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication.1 passage
• Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.1 passage
• Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed.1 passage
• Nrf2, but not β-catenin, mutation represents an early event in rat hepatocarcinogenesis.1 passage
• Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.1 passage
• Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.1 passage
• Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.1 passage
• Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease.1 passage
• Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project.1 passage
• Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells.1 passage
• Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models.1 passage
• Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice.1 passage
• Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.1 passage
• Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list.1 passage
• Optimizing hepatitis B virus screening in the United States using a simple demographics-based model.1 passage
• Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study.1 passage
• Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis.1 passage
• Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis.1 passage
• Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis.1 passage
• Organic solute transporter-β (SLC51B) deficiency in two brothers with congenital diarrhea and features of cholestasis.1 passage
• Osteopontin Takes Center Stage in Chronic Liver Disease.1 passage
• Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.1 passage
• Outcomes after multiple courses of granulocyte colony-stimulating factor and growth hormone in decompensated cirrhosis: A randomized trial.1 passage
• Outcomes of pregnancy in autoimmune hepatitis: A population-based study.1 passage
• Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.1 passage
• Oxidatively Modified Protein-Disulfide Isomerase-Associated 3 Promotes Dyskerin Pseudouridine Synthase 1-Mediated Malignancy and Survival of Hepatocellular Carcinoma Cells.1 passage
• Oxidized Albumin Triggers a Cytokine Storm in Leukocytes Through P38 Mitogen-Activated Protein Kinase: Role in Systemic Inflammation in Decompensated Cirrhosis.1 passage
• P2X1-regulated IL-22 secretion by innate lymphoid cells is required for efficient liver regeneration.1 passage
• PAPD5/7 Are Host Factors That Are Required for Hepatitis B Virus RNA Stabilization.1 passage
• PD-1 Expressing CD8+CXCR5+ Follicular T Cells Constitute Effector Rather Than Exhaustive Phenotype in Patients with Chronic Hepatitis B.1 passage
• PDLIM1 Inhibits Tumor Metastasis Through Activating Hippo Signaling in Hepatocellular Carcinoma.1 passage
• PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.1 passage
• PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.1 passage
• PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity.1 passage
• PNPLA3, CGI-58, and Inhibition of Hepatic Triglyceride Hydrolysis in Mice.1 passage
• PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate Dehydrogenase Kinase Isozyme 1 Axis.1 passage
• PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1.1 passage
• PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation.1 passage
• PTPRε Acts as a Metastatic Promoter in Hepatocellular Carcinoma by Facilitating Recruitment of SMAD3 to TGF-β Receptor 1.1 passage
• Palliative care access for hospitalized patients with end-stage liver disease across the United States.1 passage
• Paneth Cell Dysfunction Mediates Alcohol-related Steatohepatitis Through Promoting Bacterial Translocation in Mice: Role of Zinc Deficiency.1 passage
• Paracentesis-Induced Circulatory Dysfunction With Modest-Volume Paracentesis Is Partly Ameliorated by Albumin Infusion in Acute-on-Chronic Liver Failure.1 passage
• Partial splenic artery embolization for severe hepatic myelopathy in cirrhosis.1 passage
• Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.1 passage
• Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.1 passage
• Patient-Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition.1 passage
• Patient-derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management.1 passage
• Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis.1 passage
• Patient-reported outcomes in cirrhosis: A scoping review of the literature.1 passage
• Patients With Acute on Chronic Liver Failure Grade 3 Have Greater 14-Day Waitlist Mortality Than Status-1a Patients.1 passage
• Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice.1 passage
• Pediatric acute liver failure of undetermined cause: A research workshop.1 passage
• Pentraxin-3 modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury.1 passage
• Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease.1 passage
• Peribiliary Gland Niche Participates in Biliary Tree Regeneration in Mouse and in Human Primary Sclerosing Cholangitis.1 passage
• Peribiliary Glands Are Key in Regeneration of the Human Biliary Epithelium After Severe Bile Duct Injury.1 passage
• Pericentral hepatocytes produce insulin-like growth factor-2 to promote liver regeneration during selected injuries in mice.1 passage
• Perioperative immunonutrition in patients undergoing liver transplantation: a randomized double-blind trial.1 passage
• Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection.1 passage
• Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease.1 passage
• Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up.1 passage
• Persistent Biliary Hypoxia and Lack of Regeneration Are Key Mechanisms in the Pathogenesis of Post-transplant Non-anastomotic Strictures.1 passage
• Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus.1 passage
• Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.1 passage
• Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.1 passage
• Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition-associated cholestasis in mice.1 passage
• Pharmacological Activation of Nrf2 Enhances Functional Liver Regeneration.1 passage
• Pharmacological Premature Termination Codon Readthrough of ABCB11 in Bile Salt Export Pump Deficiency: An In Vitro Study.1 passage
• Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential.1 passage
• Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.1 passage
• Phenomenon of Endothelial Antibody Capture: Principles and Potential for Locoregional Targeting of Hepatic Tumors.1 passage
• Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench.1 passage
• Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth.1 passage
• Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis.1 passage
• Phosphorylation of the nuclear receptor corepressor 1 by protein kinase B switches its corepressor targets in the liver in mice.1 passage
• Physical activity and liver diseases.1 passage
• Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice.1 passage
• Plant-Based and Animal-Based Low-Carbohydrate Diets and Risk of Hepatocellular Carcinoma Among US Men and Women.1 passage
• Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells.1 passage
• Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis.1 passage
• Platelets: No longer bystanders in liver disease.1 passage
• Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis.1 passage
• Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.1 passage
• Polycystic liver disease: Hepatic venous outflow obstruction lesions of the noncystic parenchyma have major consequences.1 passage
• Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma.1 passage
• Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus.1 passage
• Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure.1 passage
• Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.1 passage
• Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis.1 passage
• Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease.1 passage
• Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles.1 passage
• Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C.1 passage
• Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort.1 passage
• Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.1 passage
• Potential of human induced pluripotent stem cells in studies of liver disease.1 passage
• Pre-Emptive Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleed: Choose Your Patient Well!1 passage
• Pre-Liver Transplant Cardiac Catheterization Is Associated With Low Rate of Myocardial Infarction and Cardiac Mortality.1 passage
• Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes.1 passage
• Predicting Low Risk for Sustained Alcohol Use After Early Liver Transplant for Acute Alcoholic Hepatitis: The Sustained Alcohol Use Post-Liver Transplant Score.1 passage
• Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.1 passage
• Predicting Postoperative Liver Dysfunction Based on Blood-Derived MicroRNA Signatures.1 passage
• Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides.1 passage
• Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach.1 passage
• Prediction of short- and long-term outcome in patients with autoimmune hepatitis.1 passage
• Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood.1 passage
• Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS).1 passage
• Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.1 passage
• Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study.1 passage
• Preferential association of hepatitis C virus with CD191 passage
• Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy.1 passage
• Pregnancy in Wilson's disease: Management and outcome.1 passage
• Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study.1 passage
• Prenatal Exposure to Perfluoroalkyl Substances Associated With Increased Susceptibility to Liver Injury in Children.1 passage
• Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.1 passage
• Present and future therapies of hepatitis B: From discovery to cure.1 passage
• Prevalence and Impact of De Novo Donor-Specific Antibodies During a Multicenter Immunosuppression Withdrawal Trial in Adult Liver Transplant Recipients.1 passage
• Prevalence of HBV Infection, Vaccine-Induced Immunity, and Susceptibility Among At-Risk Populations: US Households, 2013-2018.1 passage
• Prevalence of Undetectable Vaccine-Induced Immunity Against Hepatitis B Virus in US Adults at High Risk for Infection.1 passage
• Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988-2012.1 passage
• Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.1 passage
• Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review.1 passage
• Prevention of Cholestatic Liver Disease and Reduced Tumorigenicity in a Murine Model of PFIC Type 3 Using Hybrid AAV-piggyBac Gene Therapy.1 passage
• Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area.1 passage
• Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody.1 passage
• Prevention of portal hypertension: from variceal development to clinical decompensation.1 passage
• Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use.1 passage
• Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning.1 passage
• Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium.1 passage
• Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension.1 passage
• Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.1 passage
• Prognosis of acute variceal bleeding: Is being on beta-blockers an aggravating factor? A short-term survival analysis.1 passage
• Prognosis of untreated hepatocellular carcinoma.1 passage
• Prognostic Role of Ammonia in Patients With Cirrhosis.1 passage
• Prognostic Value of B-Type Natriuretic Peptide in Liver Transplant Patients: Implication in Posttransplant Mortality.1 passage
• Prognostic Value of the1 passage
• Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum.1 passage
• Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.1 passage
• Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1.1 passage
• Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.1 passage
• Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma.1 passage
• Prohibitin 1 suppresses liver cancer tumorigenesis in mice and human hepatocellular and cholangiocarcinoma cells.1 passage
• Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States.1 passage
• Projections of primary liver cancer to 2030 in 30 countries worldwide.1 passage
• Prominin-1 Promotes Biliary Fibrosis Associated With Biliary Atresia.1 passage
• Promoterless, Nuclease-Free Genome Editing Confers a Growth Advantage for Corrected Hepatocytes in Mice With Methylmalonic Acidemia.1 passage
• Prospective Intraindividual Comparison of Magnetic Resonance Imaging With Gadoxetic Acid and Extracellular Contrast for Diagnosis of Hepatocellular Carcinomas Using the Liver Imaging Reporting and Data System.1 passage
• Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.1 passage
• Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant.1 passage
• Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample.1 passage
• Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.1 passage
• Prospective validation of Baveno V definitions and criteria for failure to control bleeding in portal hypertension.1 passage
• Prospective validation of ab initio liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection.1 passage
• Prospero-related homeobox 1 drives angiogenesis of hepatocellular carcinoma through selectively activating interleukin-8 expression.1 passage
• Proteasomal Degradation of Enhancer of Zeste Homologue 2 in Cholangiocytes Promotes Biliary Fibrosis.1 passage
• Protective and Detrimental Roles of p38α Mitogen-Activated Protein Kinase in Different Stages of Nonalcoholic Fatty Liver Disease.1 passage
• Protein arginine methyl transferase 1- and Jumonji C domain-containing protein 6-dependent arginine methylation regulate hepatocyte nuclear factor 4 alpha expression and hepatocyte proliferation in mice.1 passage
• Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.1 passage
• Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.1 passage
• Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition.1 passage
• Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches.1 passage
• Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis.1 passage
• Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C.1 passage
• Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites.1 passage
• Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.1 passage
• Pulse Oximetry Is Insensitive for Detection of Hepatopulmonary Syndrome in Patients Evaluated for Liver Transplantation.1 passage
• Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients.1 passage
• Quality Measures, All-Cause Mortality, and Health Care Use in a National Cohort of Veterans With Cirrhosis.1 passage
• Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases.1 passage
• Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis.1 passage
• Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.1 passage
• Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection.1 passage
• RBMY, a novel inhibitor of glycogen synthase kinase 3β, increases tumor stemness and predicts poor prognosis of hepatocellular carcinoma.1 passage
• RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production.1 passage
• RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection.1 passage
• RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2.1 passage
• RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis.1 passage
• RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding.1 passage
• Racial/ethnic disparities in wait-list outcomes are only partly explained by socioeconomic deprivation among children awaiting liver transplantation.1 passage
• Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses.1 passage
• Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.1 passage
• Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis.1 passage
• Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.1 passage
• Randomized trial of 1-week versus 2-week intervals for endoscopic ligation in the treatment of patients with esophageal variceal bleeding.1 passage
• Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.1 passage
• Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B.1 passage
• Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.1 passage
• Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.1 passage
• Ras Homolog Family Member F, Filopodia Associated Promotes Hepatocellular Carcinoma Metastasis by Altering the Metabolic Status of Cancer Cells Through RAB3D.1 passage
• Re-evaluation of hepatitis B virus clinical phases by systems biology identifies unappreciated roles for the innate immune response and B cells.1 passage
• Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.1 passage
• Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging?1 passage
• Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis.1 passage
• Receipt of a pediatric liver offer as the first offer reduces waitlist mortality for adult women.1 passage
• Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?1 passage
• Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.1 passage
• Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis.1 passage
• Reciprocal Regulation Between Forkhead Box M1/NF-κB and Methionine Adenosyltransferase 1A Drives Liver Cancer.1 passage
• Recombinant relaxin protects liver transplants from ischemia damage by hepatocyte glucocorticoid receptor: From bench-to-bedside.1 passage
• Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group.1 passage
• Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis.1 passage
• Recurrence of Hereditary Hemorrhagic Telangiectasia After Liver Transplantation: Clinical Implications and Physiopathological Insights.1 passage
• Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study.1 passage
• Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.1 passage
• Redefining Cirrhotic Cardiomyopathy for the Modern Era.1 passage
• Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action.1 passage
• Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.1 passage
• Refitting the Model for End-Stage Liver Disease for the Eurotransplant Region.1 passage
• Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.1 passage
• Regional Differences in Human Biliary Tissues and Corresponding In Vitro-Derived Organoids.1 passage
• Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy.1 passage
• Regulation of mechanosensitive biliary epithelial transport by the epithelial Na(+) channel.1 passage
• Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma.1 passage
• Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis.1 passage
• Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham Score.1 passage
• Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD.1 passage
• Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study.1 passage
• Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride.1 passage
• Renal Function Parameters and Serum Sodium Enhance Prediction of Wait-List Outcomes in Pediatric Liver Transplantation.1 passage
• Reply.3 passages
• Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.1 passage
• Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.1 passage
• Research methodologies to address clinical unmet needs and challenges in alcohol-associated liver disease.1 passage
• Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors.1 passage
• Resolution of liver fibrosis requires myeloid cell-driven sinusoidal angiogenesis.1 passage
• Response to "Serum bioavailable 25-hydroxyvitamin D levels correlate with hepatocellular carcinoma survival".1 passage
• Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.1 passage
• Responsible Inclusion of Pregnant Individuals in Eradicating HCV.1 passage
• Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study.1 passage
• Retargeting of bile salt export pump and favorable outcome in children with progressive familial intrahepatic cholestasis type 2.1 passage
• Retinoic Acid Receptor-β Is Downregulated in Hepatocellular Carcinoma and Cirrhosis and Its Expression Inhibits Myosin-Driven Activation and Durotaxis in Hepatic Stellate Cells.1 passage
• Retinoic acid-related orphan receptor alpha reprograms glucose metabolism in glutamine-deficient hepatoma cells.1 passage
• Retinoid regulation of antiviral innate immunity in hepatocytes.1 passage
• Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.1 passage
• Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.1 passage
• Risk Prediction Models for Post-Operative Mortality in Patients With Cirrhosis.1 passage
• Risk Stratification Based on Chronic Liver Failure Consortium Acute Decompensation Score in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.1 passage
• Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study.1 passage
• Risk for alcoholic liver cirrhosis after an initial hospital contact with alcohol problems: A nationwide prospective cohort study.1 passage
• Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes.1 passage
• Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America.1 passage
• Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort.1 passage
• Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.1 passage
• Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.1 passage
• Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-Up of Population Cohorts.1 passage
• Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial.1 passage
• Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology.1 passage
• Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study.1 passage
• Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.1 passage
• Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.1 passage
• Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension.1 passage
• Rotavirus Reassortant-Induced Murine Model of Liver Fibrosis Parallels Human Biliary Atresia.1 passage
• SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR.1 passage
• SIRT1 Regulates N1 passage
• SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells.1 passage
• SIRT1/HSF1/HSP pathway is essential for exenatide-alleviated, lipid-induced hepatic endoplasmic reticulum stress.1 passage
• SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases.1 passage
• STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?1 passage
• Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11.1 passage
• Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis.1 passage
• Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.1 passage
• Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data.1 passage
• Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.1 passage
• Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials.1 passage
• Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection.1 passage
• Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.1 passage
• Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia.1 passage
• Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.1 passage
• Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease.1 passage
• Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis.1 passage
• Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: Nationwide surveys (KNHANES 2008-2011).1 passage
• Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.1 passage
• Schistosoma mansoni Egg-Secreted Antigens Activate Hepatocellular Carcinoma-Associated Transcription Factors c-Jun and STAT3 in Hamster and Human Hepatocytes.1 passage
• Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins.1 passage
• Self-assembled liver organoids recapitulate hepatobiliary organogenesis in vitro.1 passage
• Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study.1 passage
• Serologic responses and effectiveness of hepatitis A vaccination among human immunodeficiency virus-positive individuals during the outbreak of acute hepatitis A.1 passage
• Serum Alanine Aminotransferase Elevations in Survivors of Childhood Cancer: A Report From the St. Jude Lifetime Cohort Study.1 passage
• Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.1 passage
• Serum Bioavailable, Rather Than Total, 25-hydroxyvitamin D Levels Are Associated With Hepatocellular Carcinoma Survival.1 passage
• Serum Hepatitis B Virus RNA: A New Potential Biomarker for Chronic Hepatitis B Virus Infection.1 passage
• Serum Laminin γ2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular Carcinoma.1 passage
• Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression.1 passage
• Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis.1 passage
• Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.1 passage
• Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.1 passage
• Serum microcystin levels positively linked with risk of hepatocellular carcinoma: A case-control study in southwest China.1 passage
• Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.1 passage
• Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents.1 passage
• Sex-Specific Regulation of Interferon-γ Cytotoxicity in Mouse Liver by Autophagy.1 passage
• Sexual Dysfunction and Sex Hormone Abnormalities in Patients With Cirrhosis: Review of Pathogenesis and Management.1 passage
• Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study.1 passage
• Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.1 passage
• Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.1 passage
• Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.1 passage
• Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.1 passage
• Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients.1 passage
• Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.1 passage
• Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma.1 passage
• Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B.1 passage
• Significance of oliguria in critically ill patients with chronic liver disease.1 passage
• Significant reduction in end-stage liver diseases burden through the national viral hepatitis therapy program in Taiwan.1 passage
• Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.1 passage
• Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2).1 passage
• Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.1 passage
• Simultaneous Heart-Liver Transplantation for Congenital Heart Disease in the United States: Rapidly Increasing With Acceptable Outcomes.1 passage
• Single-cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma.1 passage
• Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells.1 passage
• Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α.1 passage
• Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice.1 passage
• Sirtuin-1/Mitochondrial Ribosomal Protein S5 Axis Enhances the Metabolic Flexibility of Liver Cancer Stem Cells.1 passage
• Small Dense Low-Density Lipoprotein Cholesterol Predicts Cardiovascular Events in Liver Transplant Recipients.1 passage
• Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase.1 passage
• Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype.1 passage
• Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection.1 passage
• Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.1 passage
• Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection.1 passage
• Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.1 passage
• Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed.1 passage
• Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.1 passage
• Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.1 passage
• Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.1 passage
• Soluble Adenylyl Cyclase Regulates Bile Salt-Induced Apoptosis in Human Cholangiocytes.1 passage
• Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell-Mediated Cytotoxicity Against Hepatocellular Carcinoma.1 passage
• Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade.1 passage
• Sox12, a direct target of FoxQ1, promotes hepatocellular carcinoma metastasis through up-regulating Twist1 and FGFBP1.1 passage
• Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.1 passage
• Sox9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma.1 passage
• Spermidine Confers Liver Protection by Enhancing NRF2 Signaling Through a MAP1S-Mediated Noncanonical Mechanism.1 passage
• Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2.1 passage
• Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.1 passage
• Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage.1 passage
• Splicing Regulator p541 passage
• Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy.1 passage
• Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis.1 passage
• State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States.1 passage
• Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.1 passage
• Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: A population-based study.1 passage
• Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1-Nrf2-Dependent Manner.1 passage
• Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.1 passage
• Stem/progenitor cells in liver regeneration.1 passage
• Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers.1 passage
• Stochastic phenotype switching leads to intratumor heterogeneity in human liver cancer.1 passage
• Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.1 passage
• Stratification of Residual Risk of HCC Following HCV Clearance With Direct-Acting Antivirals in Patients With Advanced Fibrosis and Cirrhosis.1 passage
• Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis.1 passage
• Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling.1 passage
• Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.1 passage
• Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis.1 passage
• Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis.1 passage
• Sulfated progesterone metabolites in the pathogenesis of intrahepatic cholestasis of pregnancy: Another loop in the ascending spiral of medical knowledge.1 passage
• Suppressed farnesoid X receptor by iron overload in mice and humans potentiates iron-induced hepatotoxicity.1 passage
• Surgical Treatments of Hepatobiliary Cancers.1 passage
• Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process.1 passage
• Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis.1 passage
• Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.1 passage
• Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first-line therapies.1 passage
• Susceptibility of Rat Steatotic Liver to Ischemia-Reperfusion Is Treatable With Liver-Selective Matrix Metalloproteinase Inhibition.1 passage
• Switch-associated protein 70 protects against nonalcoholic fatty liver disease via suppression of TAK1.1 passage
• Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers.1 passage
• Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells.1 passage
• Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma.1 passage
• Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure.1 passage
• Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.1 passage
• Systemic regulation of bilirubin homeostasis: Potential benefits of hyperbilirubinemia.1 passage
• Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development.1 passage
• TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.1 passage
• TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy.1 passage
• TM6SF2 rs58542926 impacts lipid processing in liver and small intestine.1 passage
• TMEM9-v-ATPase Activates Wnt/β-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis.1 passage
• TMPRSS4 Drives Angiogenesis in Hepatocellular Carcinoma by Promoting HB-EGF Expression and Proteolytic Cleavage.1 passage
• TNF-α-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of Apoptosis Signal-Regulating Kinase 1.1 passage
• TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.1 passage
• TRIM11 promotes hepatocellular carcinogenesis through ubiquitin-proteasome mediated degradation of PHLPP1.1 passage
• TRUSS Exacerbates NAFLD Development by Promoting IκBα Degradation in Mice.1 passage
• Tacrolimus Impairs Kupffer Cell Capacity to Control Bacteremia: Why Transplant Recipients Are Susceptible to Infection.1 passage
• Targeted Apoptosis of Ductular Reactive Cells Reduces Hepatic Fibrosis in a Mouse Model of Cholestasis.1 passage
• Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice.1 passage
• Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate.1 passage
• Targeting CCl1 passage
• Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.1 passage
• Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice.1 passage
• Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function.1 passage
• Taurine up-regulated gene 1 functions as a master regulator to coordinate glycolysis and metastasis in hepatocellular carcinoma.1 passage
• Technical standards for hepatitis B virus X protein (HBx) research.1 passage
• Telemedicine in Liver Disease and Beyond: Can the COVID-19 Crisis Lead to Action?1 passage
• Telomerase Variants in Patients with Cirrhosis Awaiting Liver Transplantation.1 passage
• Telomere Dysfunction Activates p53 and Represses HNF4α Expression Leading to Impaired Human Hepatocyte Development and Function.1 passage
• Telomere length and reactive oxygen species levels are positively associated with a high risk of mortality and recurrence in hepatocellular carcinoma.1 passage
• Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study.1 passage
• Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.1 passage
• Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1.1 passage
• Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection.1 passage
• Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection.1 passage
• Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.1 passage
• Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.1 passage
• Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.1 passage
• Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.1 passage
• The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.1 passage
• The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.1 passage
• The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.1 passage
• The Antiresection Activity of the X Protein Encoded by Hepatitis Virus B.1 passage
• The Apelin-Apelin Receptor Axis Triggers Cholangiocyte Proliferation and Liver Fibrosis During Mouse Models of Cholestasis.1 passage
• The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.1 passage
• The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.1 passage
• The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study.1 passage
• The Chemosensory Function of Primary Cilia Regulates Cholangiocyte Migration, Invasion, and Tumor Growth.1 passage
• The Clinical Significance of Hepatic CD691 passage
• The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.1 passage
• The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH.1 passage
• The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin-Mediated Degradation of 3-Hydroxy-3-Methylglutaryl CoA Reductase Degradation Protein 1.1 passage
• The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis.1 passage
• The Emerging Role of B Cells in the Pathogenesis of NAFLD.1 passage
• The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis.1 passage
• The Genetic Architecture of Diet-Induced Hepatic Fibrosis in Mice.1 passage
• The Hepatitis C Virus Care Continuum: Linkage to Hepatitis C Virus Care and Treatment Among Patients at an Urban Health Network, Philadelphia, PA.1 passage
• The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.1 passage
• The IKKβ-USP30-ACLY Axis Controls Lipogenesis and Tumorigenesis.1 passage
• The Immunobiology of Receptor Activator for Nuclear Factor Kappa B Ligand and Myeloid-Derived Suppressor Cell Activation in Immunoglobulin G4-Related Sclerosing Cholangitis.1 passage
• The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility.1 passage
• The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.1 passage
• The L-α-Lysophosphatidylinositol/G Protein-Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis.1 passage
• The Long Noncoding RNA Cancer Susceptibility 9 and RNA Binding Protein Heterogeneous Nuclear Ribonucleoprotein L Form a Complex and Coregulate Genes Linked to AKT Signaling.1 passage
• The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.1 passage
• The NACSTOP Trial: A Multicenter, Cluster-Controlled Trial of Early Cessation of Acetylcysteine in Acetaminophen Overdose.1 passage
• The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.1 passage
• The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.1 passage
• The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells.1 passage
• The Pannexin 1/Purinergic Receptor P2X4 Pathway Controls the Secretion of MicroRNA-Containing Exosomes by HCV-Infected Hepatocytes.1 passage
• The Patatin-Like Phospholipase Domain Containing Protein 7 Facilitates VLDL Secretion by Modulating ApoE Stability.1 passage
• The Power of Single-Cell Analysis for the Study of Liver Pathobiology.1 passage
• The Precise Relationship Between Model for End-Stage Liver Disease and Survival Without a Liver Transplant.1 passage
• The Prevalence of Wilson's Disease: An Update.1 passage
• The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers.1 passage
• The RNA genome of hepatitis E virus robustly triggers an antiviral interferon response.1 passage
• The Role of Complement in Liver Injury, Regeneration, and Transplantation.1 passage
• The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review.1 passage
• The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis.1 passage
• The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease.1 passage
• The Role of Senescence in the Development of Nonalcoholic Fatty Liver Disease and Progression to Nonalcoholic Steatohepatitis.1 passage
• The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.1 passage
• The Role of the Intestine in the Pathogenesis of Primary Sclerosing Cholangitis: Evidence and Therapeutic Implications.1 passage
• The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia.1 passage
• The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children.1 passage
• The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.1 passage
• The Spectrum of Hepatic Involvement in Patients With Telomere Disease.1 passage
• The Spectrum of Reactive Cholangiocytes in Primary Sclerosing Cholangitis.1 passage
• The Transcription Factor ZHX2 Alleviates Nonalcoholic Steatohepatitis by Transcriptional Activation of PTEN.1 passage
• The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis.1 passage
• The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.1 passage
• The Use of Human Pluripotent Stem Cells for Modeling Liver Development and Disease.1 passage
• The Use of Rifaximin in Patients With Cirrhosis.1 passage
• The Wnt/β-catenin pathway determines the predisposition and efficiency of liver-to-pancreas reprogramming.1 passage
• The Yield and Safety of Screening Colonoscopy in Patients Evaluated for Liver Transplantation.1 passage
• The adenosine monophosphate-activated protein kinase-vacuolar adenosine triphosphatase-pH axis: A key regulator of the profibrogenic phenotype of human hepatic stellate cells.1 passage
• The animal naming test: An easy tool for the assessment of hepatic encephalopathy.1 passage
• The ascending pathophysiology of cholestatic liver disease.1 passage
• The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection.1 passage
• The biliary epithelium presents antigens to and activates natural killer T cells.1 passage
• The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.1 passage
• The camKK2/camKIV relay is an essential regulator of hepatic cancer.1 passage
• The case for immune-based approaches in biliary tract carcinoma.1 passage
• The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis.1 passage
• The clinical course of cirrhosis: The importance of multistate models and competing risks analysis.1 passage
• The continuum of hepatitis C testing and care.1 passage
• The contribution of health risk behaviors to excess mortality in American adults with chronic hepatitis C: A population cohort-study.1 passage
• The dendritic cell-T helper 17-macrophage axis controls cholangiocyte injury and disease progression in murine and human biliary atresia.1 passage
• The distribution of hepatitis B virus exposure and infection in a population-based sample of U.S. Hispanic adults.1 passage
• The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis.1 passage
• The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.1 passage
• The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.1 passage
• The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study.1 passage
• The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis.1 passage
• The hepatic, biliary, and pancreatic network of stem/progenitor cell niches in humans: A new reference frame for disease and regeneration.1 passage
• The high burden of alcoholic cirrhosis in privately insured persons in the United States.1 passage
• The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice.1 passage
• The human longevity gene homolog INDY and interleukin-6 interact in hepatic lipid metabolism.1 passage
• The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.1 passage
• The impact of hepatitis B vaccination in United States, 1999-2018.1 passage
• The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial.1 passage
• The liver-specific microRNA-122*, the complementary strand of microRNA-122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry.1 passage
• The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans.1 passage
• The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.1 passage
• The natural history of primary sclerosing cholangitis in 781 children: A multicenter, international collaboration.1 passage
• The neuroimmune guidance cue netrin-1 controls resolution programs and promotes liver regeneration.1 passage
• The nonalcoholic steatohepatitis metabotype: Imbalance of circulating amino acids and transamination reactions reflect impaired mitochondrial function.1 passage
• The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance.1 passage
• The origin of fibrogenic myofibroblasts in fibrotic liver.1 passage
• The p.Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B.1 passage
• The pathophysiology of Wilson disease visualised: A human1 passage
• The plastic cellular states of liver cells: Are EpCAM and Lgr5 fit for purpose?1 passage
• The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.1 passage
• The profile of platelet α-granule released molecules affects postoperative liver regeneration.1 passage
• The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique.1 passage
• The rise of the opioid epidemic and hepatitis C-positive organs: A new era in liver transplantation.1 passage
• The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.1 passage
• The role of hepatic resection in the treatment of hepatocellular cancer.1 passage
• The role of hepatitis E virus infection in adult Americans with acute liver failure.1 passage
• The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.1 passage
• The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice.1 passage
• The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.1 passage
• The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.1 passage
• The secretin/secretin receptor axis modulates liver fibrosis through changes in transforming growth factor-β1 biliary secretion in mice.1 passage
• The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.1 passage
• The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease.1 passage
• The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.1 passage
• The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome.1 passage
• The small GTPase Rab7 as a central regulator of hepatocellular lipophagy.1 passage
• The underreporting of hepatocellular carcinoma to the cancer register and a log-linear model to estimate a more correct incidence.1 passage
• The unfolded protein response mediates fibrogenesis and collagen I secretion through regulating TANGO1 in mice.1 passage
• The use of transjugular intrahepatic portosystemic shunt should be cautious in patients without cirrhosis with obliterative portal vein thrombosis.1 passage
• The viral hepatitis B care cascade: A population-based comparison of immigrant groups.1 passage
• The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.1 passage
• Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.1 passage
• Therapeutic Potential of TLR8 Agonist GS-9688 (Selgantolimod) in Chronic Hepatitis B: Remodeling of Antiviral and Regulatory Mediators.1 passage
• Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.1 passage
• Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.1 passage
• Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.1 passage
• Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.1 passage
• Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.1 passage
• Thioesterase Superfamily Member 2 Promotes Hepatic VLDL Secretion by Channeling Fatty Acids Into Triglyceride Biosynthesis.1 passage
• Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial.1 passage
• Thromboelastography-Guided Blood Component Use in Patients With Cirrhosis With Nonvariceal Bleeding: A Randomized Controlled Trial.1 passage
• Thyroid Hormone Signaling and the Liver.1 passage
• Time trends in the health care burden and mortality of acute on chronic liver failure in the United States.1 passage
• Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice.1 passage
• Toll-Like Receptor 8 Agonist GS-9688 Induces Sustained Efficacy in the Woodchuck Model of Chronic Hepatitis B.1 passage
• Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.1 passage
• Toward a more accurate estimate of the prevalence of hepatitis C in the United States.1 passage
• Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.1 passage
• Toward the elimination of hepatitis C in the United States.1 passage
• Transcriptional Dynamics of Hepatic Sinusoid-Associated Cells After Liver Injury.1 passage
• Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.1 passage
• Transcriptome-Wide Analysis Reveals the Landscape of Aberrant Alternative Splicing Events in Liver Cancer.1 passage
• Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcohol-Associated Hepatitis.1 passage
• Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.1 passage
• Transforming Growth Factor-β and Axl Induce CXCL5 and Neutrophil Recruitment in Hepatocellular Carcinoma.1 passage
• Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.1 passage
• Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy.1 passage
• Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients.1 passage
• Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.1 passage
• Transmembrane serine protease TMPRSS2 activates hepatitis C virus infection.1 passage
• Transmission of Rat Hepatitis E Virus Infection to Humans in Hong Kong: A Clinical and Epidemiological Analysis.1 passage
• Transplantation for Alcoholic Hepatitis: Are We Achieving Justice and Utility?1 passage
• Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial.1 passage
• Transplanting hepatitis C virus-positive livers into hepatitis C virus-negative patients with preemptive antiviral treatment: A modeling study.1 passage
• Treatment Barriers in Portopulmonary Hypertension.1 passage
• Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.1 passage
• Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy.1 passage
• Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.1 passage
• Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir.1 passage
• Treatment of bile acid amidation defects with glycocholic acid.1 passage
• Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.1 passage
• Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.1 passage
• Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States.1 passage
• Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.1 passage
• Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials.1 passage
• Trefoil Factor Family 1 Inhibits the Development of Hepatocellular Carcinoma by Regulating β-Catenin Activation.1 passage
• Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.1 passage
• Tripartite Motif-Containing 27 Attenuates Liver Ischemia/Reperfusion Injury by Suppressing Transforming Growth Factor β-Activated Kinase 1 (TAK1) by TAK1 Binding Protein 2/3 Degradation.1 passage
• Tumor Microenvironment Regulation by the Endoplasmic Reticulum Stress Transmission Mediator Golgi Protein 73 in Mice.1 passage
• Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.1 passage
• Tumor Necrosis Factor α-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.1 passage
• Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice.1 passage
• Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma.1 passage
• Tumor-Specific Transcripts Are Frequently Expressed in Hepatocellular Carcinoma With Clinical Implication and Potential Function.1 passage
• Tumor-derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro.1 passage
• Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival.1 passage
• Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.1 passage
• Two Faces of Neutrophils in Liver Disease Development and Progression.1 passage
• Type 3 Inositol 1,4,5-Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma.1 passage
• Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis.1 passage
• USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity.1 passage
• Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6.1 passage
• Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Metabolic Dysfunctions in Nonalcoholic Fatty Liver Disease in Mice.1 passage
• Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression.1 passage
• Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient-Derived Xenograft Assays.1 passage
• Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis.1 passage
• Unique Cholangiocyte-Targeted IgM Autoantibodies Correlate With Poor Outcome in Biliary Atresia.1 passage
• Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study.1 passage
• Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department.1 passage
• Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.1 passage
• Upper GI Bleeding in Cirrhotic Patients: Which Method to Search for Helicobacter Pylori Infection?1 passage
• Uptake of hepatitis C screening, characteristics of patients tested, and intervention costs in the BEST-C study.1 passage
• Use of Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis: A Systematic Review and Meta-Analysis.1 passage
• Using the Icelandic genealogical database to define the familial risk of primary biliary cholangitis.1 passage
• Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.1 passage
• VWF/ADAMTS13 Imbalance, But Not Global Coagulation or Fibrinolysis, Is Associated With Outcome and Bleeding in Acute Liver Failure.1 passage
• Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.1 passage
• Vacuolar Protein Sorting 33B Is a Tumor Suppressor in Hepatocarcinogenesis.1 passage
• Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic Patients: A Model Based on the Administrative Database.1 passage
• Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy.1 passage
• Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study.1 passage
• Valproic acid-induced hepatotoxicity in Alpers syndrome is associated with mitochondrial permeability transition pore opening-dependent apoptotic sensitivity in an induced pluripotent stem cell model.1 passage
• Value-based care in hepatology.1 passage
• Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection.1 passage
• Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases.1 passage
• Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors.1 passage
• Vasomodulators and Liver Transplantation for Portopulmonary Hypertension: Evidence From a Systematic Review and Meta-Analysis.1 passage
• Vemurafenib-induced granulomatous hepatitis.1 passage
• Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma.1 passage
• Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.1 passage
• Virtual Consultations Through the Veterans Administration SCAN-ECHO Project Improves Survival for Veterans With Liver Disease.1 passage
• Visceral adiposity increases risk for hepatocellular carcinoma in male patients with cirrhosis and recurrence after liver transplant.1 passage
• Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis.1 passage
• Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells.1 passage
• We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.1 passage
• Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study.1 passage
• When to perform hepatic resection for intermediate-stage hepatocellular carcinoma.1 passage
• Which approach is appropriate for spontaneous portosystemic shunt embolization in patients with post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy: Antegrade or retrograde?1 passage
• Workforce in hepatology: Update and a critical need for more information.1 passage
• World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.1 passage
• YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors.1 passage
• YAP suppresses gluconeogenic gene expression through PGC1α.1 passage
• YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.1 passage
• YAP1 Withdrawal in Hepatoblastoma Drives Therapeutic Differentiation of Tumor Cells to Functional Hepatocyte-Like Cells.1 passage
• Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.1 passage
• Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.1 passage
• Zebrafish abcb11b mutant reveals strategies to restore bile excretion impaired by bile salt export pump deficiency.1 passage
• Zinc finger protein 191 inhibits hepatocellular carcinoma metastasis through discs large 1-mediated yes-associated protein inactivation.1 passage
• aPKC-ι/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma.1 passage
• cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation.1 passage
• miR-210 Participates in Hepatic Ischemia Reperfusion Injury by Forming a Negative Feedback Loop With SMAD4.1 passage
• miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis.1 passage
• p300 Acetyltransferase Is a Cytoplasm-to-Nucleus Shuttle for SMAD2/3 and TAZ Nuclear Transport in Transforming Growth Factor β-Stimulated Hepatic Stellate Cells.1 passage
• qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.1 passage
• β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.1 passage
• βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin.1 passage